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Abstract 
 The nature of cancer control is changing, with an increasing emphasis, fuelled by 
public and political demand, on prevention and early diagnosis, and on the patient 
experience during and after treatment. At the same time primary care is increasingly 
promoted, by Governments and health funders worldwide, as the preferred setting 
for most health care, for reasons of increasing need, stabilising healthcare costs and 
patient preference for care close to home. It is timely, then, to consider how this can 
work for cancer control, which has long been dominated by highly technical 
interventions centred on treatment, and where the contribution of primary care has 
been largely perceived as marginal.  In this Commission, expert opinion from primary 
care and public health professionals with academic and clinical cancer expertise, 
from epidemiologists, psychologists, policy makers and from cancer specialists, has 
contributed to a detailed consideration of the evidence for cancer control provided 
in primary and community care settings. Ranging from primary prevention to end of 
life care, the scope for new models of care is explored. The strengths of primary 
care, its continuous, co-ordinated and comprehensive care for individuals and 
families, are particularly evident in prevention, and diagnosis, in shared follow-up 
and survivorship care, and in end of life care. A strong theme of integration of care 
runs throughout, and its elements, clinical, vertical and functional, as well as the 
tools needed for integrated working, are described in detail. All of this change, as it 
evolves, will need to be underpinned by new research as well as continuing and 
shared multi-professional development.   
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Part 1: Introduction 
Cancer control in high-income countries has long been dominated by highly technical, 
disease-centred interventions intended to save or prolong life. That paradigm is changing as 
health policies drive greater emphasis on public awareness, screening and early diagnosis of 
symptomatic disease as a means to further improve outcomes. At the same time more 
people are surviving cancer and will live with the long term effects of their disease and its 
treatment. Nor is this a unique problem for the wealthiest nations. Middle-income countries 
are starting to face the same challenges, as non-communicable diseases, especially cancer, 
become a more prominent health care issue for their populations.   
 
For a long time the role of primary care in cancer was largely perceived as peripheral, but as 
prevention, diagnosis, survivorship and end of life care assume greater significance, so the 
defining characteristics of primary care become more important. Care that is more patient-
centred brings with it considerations of patient choice and convenience, but also the whole 
person approach that patients seek. Health services striving for affordable cancer care seek 
optimal models of care delivery, which may require the re-engineering of some deeply held 
socio-medical cultural practices.1 
 
 
Figure 1.1 The Cancer Journey (courtesy of Cancer Care Ontario) 
 
The purpose of this Commission is to distil the evidence for the effectiveness of 
interventions for cancer control based in primary care at each stage of the cancer journey 
(Fig 1.1), and to consider how cancer care might be delivered differently in the future. It 
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considers how and whether health policy for cancer control will help or hinder such change. 
Lastly it considers the implications for the future education and training of doctors and 
identifies emerging examples of good practice world-wide. The Commission brings together 
leading members of the international primary care cancer community, together with cancer 
specialists and policy researchers. We have elected to restrict our review to high income 
countries, and largely to countries with universal health care systems, since these have a 
more clearly defined and discrete primary care element to their services.  
 
The current and future cancer burden from the primary care perspective 
The lifetime risk of cancer in the UK is now 50%.2 The incidence of many cancers is 
increasing, as a result of lifestyle and environmental factors as well as an increasingly aged 
population, especially as the ‘baby boom’ generation reaches its 7th and 8th decades (Figs 
1.2, 1.3). 
 
 
Figure 1.2 Colorectal cancer - world Age-Standardised Incidence Rates per 100,000 
Population, Females, By Country (Cancer Research UK) 
 
 
Figure 1.3 Colorectal cancer - world Age-Standardised Incidence Rates per 100,000 
Population, Males, By Country (Cancer Research UK) 
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 Prevalence is rising too, as 10-year cancer-specific survival has increased from one in four in 
the 70s, to one in two today. The Dutch Cancer Society has predicted a 61% increase in 
cancer survivors between 2010 and 2020.3 
 
 A cancer diagnosis is a relatively common event in primary care: a PCP with 2000 patients 
currently sees 6-8 new cases per year in total, comparable to the number of new cases of 
diabetes mellitus for example, and twice as frequent as new cases of stroke. The difference, 
of course, is that cancer is a heterogenous entity and any single cancer type a relatively rare 
event, each characterised by different presenting signs and symptoms. The same PCP can 
expect only one case of each of the common cancers (colorectal, prostate, breast, lung) in 
any year and may only see one or two of some rarer cancers during their entire professional 
career. As survival improves, so prevalence of cancer in the practice population increases. At 
present the PCP with 2000 patients will have around 70 patients with or surviving cancer, 
and this is predicted to double by 2040.4 In comparison he or she will currently look after 
120 patients with diabetes mellitus. 
 
The diagnostic process for cancer has now been well described and broken down into its 
component elements (Fig 1.4) together with much needed clarity about how those elements 
re best defined.5  This model underpins much of the more recent thinking about the process 
of cancer diagnosis and, taken together with the theoretically-derived Model of Pathways to 
Treatment,6 informs our detailed consideration of the diagnostic process contained in parts 
3 and 4, as well as the patient help-seeking dimension addressed in part 2. 
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Figure 1.4 An illustration of the overall milestones and time intervals in the route from first 
symptom until start of treatment 7 
A minority of cancers are detected through screening programmes, which in most high-
income countries operate for colorectal, breast and cervical cancer. In the UK and Australia 3 
in 10 breast cancers are diagnosed this way; only 1 in 20 colorectal cancers are detected 
through screening.8 In the second part of this Commission we consider in more detail the 
role played by primary care in screening programmes. 
 
Around 85% of cancers are diagnosed following symptomatic presentation to a PCP 9Over 
90% of patients with a cancer that typically has characteristic symptoms or signs (e.g. breast, 
melanoma) are referred to a specialist after one or two PCP consultations. For those with a 
cancer that lacks a distinctive symptom signature (e.g. lung, myeloma, pancreas) a third or 
more will have three or more PCP consultations before being referred.10 One consequence is 
that for such cancers, presentation to specialist care is more likely to be as an emergency, 
rather than a planned referral,8 with associated poorer clinical outcome and patient 
experience.  
 
The diverse nature of cancer symptoms is the key challenge for PCPs in making a cancer 
diagnosis, namely the accurate and timely assessment of symptoms and signs that are much 
more frequently caused by less serious illnesses. In several countries, urgent referral 
pathways have been developed to facilitate assessment of the symptomatic patient. 
Because up to half of patients with some cancers do not have alarm symptoms,11 there is 
increasing interest in pathways for the assessment of those with non-specific or non-alarm 
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symptoms. These assessment pathways are considered in more detail in part 8. Whilst 
achieving a prompt diagnosis of cancer is a priority, the diagnostic pathway shown in Figure 
1.4 conceals many complexities, For example, short diagnostic intervals are associated with 
more advanced disease and poorer survival – the waiting time paradox described in detail in 
part 3.  
 
A significant minority of all cancers (24% in England)8 are diagnosed following attendance at 
emergency departments (ED) of acute hospitals or emergency admission to hospital. The 
extent to which these patients have interacted with primary care is not well understood, 
though they are more likely to come from a deprived background and more frequently use 
the ED as a source of primary health care.12, 13 14 
 
Lastly, an unknown proportion of cancers is diagnosed incidentally, either because the 
symptoms were not caused by the cancer, or during the course of investigation for an 
unrelated problem. These cancers may be important, however, as they may be earlier stage 
and more amenable to treatment.[15 On the other hand, the cancer may not become a 
health problem in the patient’s lifetime. We consider more fully the PCP’s role in judicious 
use of diagnostic tests in Part 4. Interest in this dimension of the overdiagnosis debate is 
growing as patients undergo testing for cancer at increasingly lower levels of risk. 
Nevertheless, the scale and significance of overdiagnosis in symptomatic patients remains 
poorly understood. 
 
Over the next ten years, the primary care workload associated with cancer will increase 
across the entire cancer pathway. Health care systems are increasingly introducing guidance 
on urgent referral for investigation for suspected cancer. The recently revised English 
National Institute for Health and Care Excelence (NICE) guidelines16, have set an explicit 
threshold of risk in adults of 3%, which may double the number of patients who are tested 
or referred with the more subtle patterns of symptoms and signs of cancer. Earlier guidance 
from NICE advising CA125 as the initial test for suspected ovarian cancer resulted in a 
threefold increase in test requests from primary care, though only half of all patients with 
ovarian cancer were referred by the urgent pathway for suspected cancer.17 Diagnostic 
testing may also be inconclusive, giving rise to the need for repeat tests after intervals that 
remain to be defined and evaluated.    
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The resolution of these dilemmas will require much closer working between PCPs and  
specialists for cancer diagnosis, as envisaged by the RCGP for the UK.18  This will also have an 
impact on the way in which workload is managed within the practice. In Part 7 of this 
Commission we review in detail the ways in which integration between primary and 
specialist care can work for cancer control.  
 
For patients undergoing treatment whether primary or for relapse, the impact on workload 
in primary care is unlikely to change significantly.  Patients with acute complications of 
cancer treatment such as the consequences of myelosuppression, neutropenic sepsis, 
nausea and vomiting and diarrhoea will continue to be managed by acute oncology 
services.19 Some patients may, in spite of advice to use the emergency arrangements for 
their oncology service provider, first contact their PCP about treatment-related effects, such 
as neutropenic sepsis, especially if their treatment is being delivered in a community setting. 
PCPs will require the necessary skills and organisational capacity to assess the patient 
accurately and arrange prompt access to treatment.20  
 
The future configuration of long-term follow up after cancer treatment, and the role of 
primary care in this, remains unclear, though moves to reduce the role of the specialist in 
follow-up of patients with breast and other cancers are likely to result in an increasing role 
for GPs. Taking the example of breast cancer, the consensus is that routine follow-up aimed 
at detecting metastatic disease before the patient is aware of symptoms is not effective in 
improving survival.  NICE guidance for other aspects of breast cancer follow-up simply invites 
a discussion between the patient and her doctors to decide what to do in the event of 
recurrence, but emphasises the value of psychological support, which can be achieved by 
continued contact with the breast cancer team.21 For example, The European Society of 
Medical Oncology guidelines on follow-up of patients after initial treatment of primary 
breast cancer acknowledge a lack of clinical trials evidence to support any particular follow-
up policy but suggest a schedule which includes annual follow-up beyond the fifth year.22   
 
The research evidence on which shared care or transfer of care for follow-up is based is no 
longer recent. In the meantime the treatment options for metastatic breast cancer have 
widened considerably while long term bone and cardiac sequelae are increasingly 
recognised. In the future the quality of follow-up care for cancer will be measured by its 
ability to ensure appropriate monitoring and timely receipt of these newer treatments.  
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A further development where the role of the PCP may increase in importance is as navigator 
for access to specialist services. The gatekeeping function and the role of navigator in 
integrated care are considered in parts 7 and 8 of this Commission.   
 
Two other factors are likely to increase the cancer workload in primary care.  One is the 
recognition that elderly patients are less likely to receive timely diagnosis and treatment for 
cancers even when a lack of comorbidity would otherwise permit it.23 The second is the 
impact of continued efforts to redress socio-economic inequalities in access to cancer care. 
Socio-economic inequalities impair timely access to lung cancer treatment but do not affect 
the nature of the treatment.24  
 
What is primary health care and how is it evolving? 
Most countries in the developed world have health care systems with an identifiable 
component that is primary care. Primary care is defined by the WHO as ‘first-contact, 
accessible, continued, comprehensive and coordinated care. First-contact care is accessible at 
the time of need; ongoing care focuses on the long-term health of a person rather than the 
short duration of the disease; comprehensive care is a range of services appropriate to the 
common problems in the respective population and coordination is the role by which primary 
care acts to coordinate other specialists that the patient may need’.25 Primary care is 
commonly, though to a varying extent, provided by clinicians who are generalists, as distinct 
from those with specialist expertise restricted to a specific area of clinical practice (e.g. 
cardiology, palliative care).  
 
While the organisation and functions of primary health care differ from one country to 
another due to historical developments and different economic, social and cultural 
circumstances the general practitioner (GP) or primary care physician (PCP) has been, and 
often still is, an essential element and often most significant single player in its delivery. 
However, primary care is now largely delivered through multidisciplinary teams (centred 
around general or family practices) that comprise up to 30 individual professionals, each 
making complementary contributions to patient care. PCPs, nurses, pharmacists, physical 
therapists and many others may contribute to the care of any individual. Whether they 
operate as a team or team of teams is an important question that is not fully understood.26 
 
The enduring and universal strength of primary care is a core commitment to generalism. 
This is supported by a continuous longitudinal relationship with patients, and the PCP’s 
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clinical expertise with the often undifferentiated and ill-defined nature of the problems 
presented.  Analyses of data from the United States, United Kingdom and Europe have 
shown that having more PCPs per capita is associated not only with better health outcomes, 
but also with less expensive services and better patient experience.27 
 
Worldwide, primary care practice has had to adapt continually to the changing political and 
social context in which it operates. In England, these adaptations were demonstrated by the 
creation of a professional body and mandatory post-graduate training programmes in the 
1970s, incentives to commission health services from the 1990s, and an increased emphasis 
on performance-related pay, quality, regulatory and governance mechanisms over the last 
decade. While societal changes impacting on primary care practice may have subtle 
variations between countries, they fall into four main groups: demographic pressure, new 
technology, patient expectations and expertise, and financial pressure.28  
 
Internationally, ageing populations have led to increasing demand for complex medical care 
for more people living with multiple long-term conditions. Low- and middle-income 
countries face the added burden of burgeoning incidence rates of non-communicable 
diseases.29 With the widespread use of mobile phones and the internet, technological 
advances offer new platforms for people to access health information and communicate 
with primary care, as well as for monitoring symptoms and treatments, and to support and 
motivate health-behaviour change. Despite this, primary care systems have often been slow 
to adopt technological changes and redesign services.30 At the same time, patient 
expectations about access to care continuously rise, and there is growing evidence of the 
‘expert patient’ who expects a partnership model of decision-making, and more 
responsibility for managing their own health and healthcare.29 Finally, while the needs of 
patients and populations continue to grow in complexity and volume, publically-funded 
health care systems are under increasing financial pressure with constrained spending due 
to the global economic recession.  
 
In response, primary care practice has evolved to be at the core of a multi-professional 
primary care team in many countries. Nurses and allied health professionals now undertake 
many routine and non-clinical tasks and a broader range of activities, allowing PCPs to 
increasingly focus on complex cases. In the United Kingdom, the Royal College of General 
Practitioners (RCGP) has pledged by 2022 to develop the GP (PCP) role as an ‘expert 
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generalist’ by: developing new generalist-led integrated services to deliver personalised, 
cost-effective care; expanding and enhancing the capacity and skills of the primary care 
workforce to provide complex care, and supporting flexible models of care with the 
organisational development of community-based practices, teams and networks.18 New 
Zealand, the Netherlands, Canada and the United States already have examples of multi-
practice organisations delivering quality primary care on a greatly increased scale.31 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Inequalities and primary health care 
Inequalities in the availability of health care have long been recognised. Tudor Hart first 
proposed the inverse care law in 1971, stating that ‘the provision of good medical care tends 
to vary inversely with the need for it in the population served’. This law, formulated in 
relation to socio-economic deprivation, appears to operate through an interaction of 
patient, physician and service factors. Primary care patients who are socio-economically 
deprived have more long term health problems, psychological problems and multi-morbidity 
than those from least deprived areas, but wait longer for scheduled access to a PCP, have 
shorter clinical encounters, consult doctors who are more stressed, and are less satisfied 
with the experience.32 
 
Socio-economic inequalities in cancer care and outcomes are increasingly recognised, but 
their causes are less well understood. There is evidence for differences in treatment but 
speed of diagnosis, patient factors and biological differences may all play a part.33 In lung 
Panel 1 
 Primary care is now characterised by multi-professional teams led by expert 
generalists providing increasingly complex medical care to people who often 
have multiple long-term conditions 
 Primary care practices increasingly collaborate in networks and federations 
to provide more cost-effective care at scale 
 Two aspects of cancer care where primary care involvement is growing 
rapidly are in early identification of patients with possible cancer and in 
providing long-term care to cancer survivors. 
 Primary care should play an important role in reducing current socio-
economic inequalities in access, particularly to specialist health care. 
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cancer, these differences are more pronounced in patients whose symptoms are ill-defined34 
suggesting differences at the level of the patient / clinician interaction.   
 
Some insights into how primary care might contribute to these observed socio-economic 
inequalities, and how they might be redressed, can be drawn from the wider research 
literature. An analysis of physician utilisation by income in 21 OECD countries, drawing on 
data from national surveys or the European Community Household Panel, found no inequity, 
or a pro-poor distribution, for PCP visits. In all countries for which data were available, 
however, there was pro-rich inequity for specialist consultations, after controlling for 
differences in need.35 When educational attainment is used as a measure of socio-economic 
status, comparable findings result. After adjustment for health status, there is equity in 
contacts with primary care but a pro-higher education inequity in specialist visits.36 For 
countries with gatekeeping systems, the referral process may itself may be generating 
inequalities37, being more challenging for deprived patients to navigate, though the 
readiness of some PCPs to refer may also be socio-economically patterned.38 Others, 
however, while confirming a socioeconomic gradient in access to specialist care, have 
argued that part of the association is explained by geographical clustering of more affluent 
patients and specialist services. For cancer, inequalities are apparent in longer intervals from 
first presentation to diagnosis for women and the elderly.39 
 
The geographical distribution of PCPs is a policy concern for many countries.  Inequalities in 
per capita availability of primary care physicians between countries with Universal Health 
Care Systems (UHCS) are small40, and within countries appears not to be strongly socio-
economically patterned. For some countries, such as Canada and Australia, however, rurality 
creates great inequalities in health care availability.40 However, policies that strive for per 
capita equity of PCP availability fail to address the considerably greater illness burden among 
deprived populations. This problem has been conceptualised as the ‘Deep End’ of primary 
care.41 Even with per capita equity of PCP provision, the capacity to effectively manage the 
complex health care needs of a practice population care is proportionately less in practices 
serving deprived populations. One consequence for cancer is that women from deprived 
areas with breast cancer are twice as likely to be admitted to hospital for unrelated 
conditions in the two years after completing treatment.42 Cervical screening uptake is also 
lower in practices located in SE deprived areas. 
 
15 
 
Studies of quality of primary health care in deprived populations report conflicting findings, 
with lower uptake of cervical cancer screening and lower scores for interpersonal care and 
patient satisfaction, but no difference in quality of chronic disease management.43  
Nevertheless, the areas that experience the greatest problems with PCP recruitment and 
retention tend to be deprived urban areas in the UK, and rural areas in Canada and Australia.  
 
These inequities assume greater importance in countries with universal health care systems 
where gatekeeping is often a prominent feature.  For cancer, access to urgent assessment is 
increasingly restricted by specific referral criteria, but there is an ecological association 
between gatekeeping and cancer-specific mortality, which needs to be better understood 
and is addressed in detail in Part 8.44  
 
Conclusions 
Primary care is first contact and continuing care provided in community settings by multi-
professional teams led by expert generalist physicians working in practices. These will 
increasingly join together in federations or networks to provide care on a greater scale. 
Cancer and its consequences will be an increasingly prominent part of the primary care 
workload in the future, while the breadth of involvement of PCPs in cancer care will also 
increase. PCPs will be at the forefront in addressing the persistent socio-economic and age 
inequalities in cancer care.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Part 2: The role of the PCP in prevention, screening and promoting help-seeking 
PCPs sit at the frontline of healthcare services, and have important roles in primary 
prevention and screening for cancer. In this section we review the evidence for the 
effectiveness of their involvement, although these efforts should be ideally co-ordinated 
with broader public health efforts. 
 
 GPs have established roles and efficacy in reducing smoking and harmful alcohol use 
 With the advent of the obesity epidemic it is important that GPs and primary care 
teams develop more effective strategies targeting weight loss and physical activity. 
 There are complex cognitive, emotional and behavioural determinants of symptomatic 
presentation for cancer – it is important that GPs have an understanding of these 
psychological processes in their patients if they are to deliver effective advice to 
promote early presentation 
 Public awareness campaigns are able to increase the frequency with which patients 
present to primary care with potentially significant symptoms – it is vital that campaign 
organisers work closely with primary care in developing the most effective and 
integrated programmes 
 GPs have multiple roles in cancer screening, including promotion of uptake and 
informed choice, information provision and involvement with follow-up of test-positive 
individuals. Engagement with primary care is an important priority for cancer screening 
programmes 
Panel 2 
 
Primary prevention 
Considerable evidence has accumulated in the efficacy or otherwise of PCP-based 
prevention strategies - although there is significant variation in the level of change achieved, 
with effect sizes usually described as ‘small or moderate’.45  Multifaceted interventions are 
probably the most effective, as more barriers to change can be addressed. Interventions 
delivered to patients at low risk may, however, only be of marginal benefit.46 Further, few 
such studies base their intervention strategies on theories of behaviour change.47PCP-based 
interventions can be usefully divided into those that are directly delivered by the PCP (for 
example brief advice with or without drug treatment), and more intensive interventions that 
the PCP can recommend to the patient and in some cases make a referral.  The Ask, Advise 
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and Act framework48 has been widely used in the smoking cessation field but could also be 
applied to other areas of behaviour change (Table 2.1). 
 
Table 2.1 The ‘3As’ approach to prevention 
 
Smoking 
It is now generally recognised that brief interventions based in primary care have the 
potential to reduce rates of smoking.  Brief advice, as well as print-based, self-help 
interventions, have been shown to have a modest but significant effect49, 50  Combinations of  
brief advice, counselling and prescribing nicotine replacements appear to be particularly 
effective.51 We know less about how primary care efforts will work alongside recent 
initiatives, such as the introduction of e-cigarettes.52  Primary care in the UK has been 
innovative in contributing to the establishment of smoking cessation clinics - for which there 
is a solid evidence base.  
 
Alcohol 
Brief interventions in primary care can reduce alcohol consumption - evidence for this has 
accumulated over several decades, and the studies have wide applicability in primary care 
settings.53 Recent interest has focused particularly on motivational interviewing, which 
appears to out-perform simple advice from a PCP, although more evidence is needed before 
it is incorporated into routine practice.54  We also need to know more about the best  
interventions in key sub-groups (women, older and younger drinkers, minority ethnic 
groups, dependent/co-morbid drinkers), and the ideal intervention length and frequency to 
maintain longer-term effectiveness.55  
 
Diet and obesity 
In contrast to smoking and alcohol, there have been fewer studies of primary care 
intervention in diet and obesity, although a recent study found that a health professional 
recommendation was associated with higher likelihood of weight loss attempts.56 
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Nevertheless, evidence exists for the efficacy of primary care based programmes, 
particularly when combined with interventions from other agencies,57 although referral to 
commercial programmes may be more cost-effective.58  Weight reduction interventions are 
poorly documented in UK primary care, and access to appropriate programmes may be a key 
issue.  
 
Physical activity 
In the UK, NICE guidance (2013) recommends brief physical activity advice in primary care, 
using an approach based on the Ask, Advise, Act framework.48  Advice and counselling in 
general practice can lead to increases in physical activity (at 12 months),59  although little is 
known about the amount of physical activity advice provided in UK general practice. Many 
studies have examined the concept of ‘exercise on prescription’ in which PCPs ‘prescribe’ 
exercise from a third party provider; while this approach is generally acceptable to PCPs and 
patients, we lack a comprehensive picture of its effectiveness (for example, its impact in 
hard-to-reach groups). A recent systematic review concluded that physical activity 
promotion to sedentary adults (recruited in primary care) significantly increases physical 
activity levels at 12 months, although there was insufficient evidence to draw distinctions 
between exercise referral schemes and counselling interventions.60 
 
Patient appraisal and help-seeking in primary care 
Given that most cancer diagnoses come from patients presenting symptomatically in 
primary care, a better understanding of the processes influencing the length of time 
between the patient noticing a symptom and seeking medical advice (the patient interval) is 
an important step in developing strategies to minimise diagnostic delay.  
 
Qualitative studies interviewing patients after diagnosis, have identified three elements in 
prolonged patient intervals: not recognising the seriousness of the symptom, fear of 
receiving a cancer diagnosis, and reluctance to interact with the primary care system.61 
Community-based studies using standardised measures of awareness in population-based 
samples reach similar conclusions:62  people have poor recall of potential cancer symptoms 
other than ‘lump’, a significant minority say they would avoid a cancer diagnosis, and many 
report a range of barriers to help-seeking. All three domains have been shown to be 
modestly associated with ‘anticipated delay’ (the time people say they would wait before 
seeking help if they experienced a particular symptom).63 Newer studies have combined 
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large-scale surveys designed to quantify symptom prevalence and attribution, with 
qualitative studies designed to explore patients’ views in more detail.64, 65 These confirm that 
people who are experiencing cancer ‘alarm’ symptoms rarely recognise them as cancer; 
among those who do, some are too fearful of cancer to seek help, and that among those 
who consider seeking help, barriers such as worry about seeming hypochondriacal can put 
them off.  These delay processes can be broadly classified as cognitive, emotional, and 
behavioural. 
 
Understanding extended patient intervals 
The cognitive domain (not recognising the symptom as serious) is especially important; more 
than half of people aged over 50 report experiencing at least one alarm symptom in the past 
three months,63 and very few attribute such symptoms to cancer or even perceive them as 
serious.  A ‘normalisation’ process means that most symptoms are attributed to other 
factors (eg other illnesses, ageing, stress).  Previous reassurance from the PCP about the 
same type of symptom can also reduce the likelihood that the patient will interpret the 
symptom as serious.66  The emotional domain (fear of a cancer diagnosis) is less often cited 
as a reason for avoiding help-seeking, but where it is, it can cause lengthy delays. In 
community surveys, around 10% of people said they would not want to know if they had 
cancer, and almost half thought that cancer treatment was worse than cancer. A recent 
analysis found that fatalistic views of cancer were associated with a substantially greater risk 
of advanced stage diagnosis in lung and colorectal cancer.67  The behavioural domain refers 
to the barriers (perceived or actual) to help-seeking behaviour.  In many community surveys, 
worry about ‘wasting the doctor’s time’ emerges as a barrier, and this is particularly 
common in the UK although the exact underlying motivation is not clear. Having had a 
previous negative investigation for the same symptom can also be a deterrent to help-
seeking; often because patients feel fully reassured, but sometimes because previous 
consultations about the same symptom have been frustrating,65 or patients worry that the 
doctor would be dismissive of further questions about the same symptom.63, 64  Other 
barriers cited in studies asking the public why they might avoid help-seeking include 
embarrassment about the symptom or worry about an examination, as well as practical 
difficulty making a PCP appointment; although these are rarely mentioned in symptom 
surveys or in patient interviews.  
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Implications for interventions in primary care 
It is important that PCPs have an understanding of the cognitive, emotional and behavioural 
processes that tend to increase risk of delay in symptomatic presentation in their patients.  
PCPs have an obvious role in educating patients about symptoms to look out for, and there 
may be ‘teachable moments’ for such educational interventions, such as after a negative 
symptomatic investigation or after discussion of screening.   Reducing excessive cancer fear 
is more challenging; but if PCPs are able to help patients discuss their worries about cancer, 
this could help them to face a diagnosis. PCPs should be well-placed to address barriers to 
attendance in the doctor-patient interactions.  In general terms, primary care systems that 
welcome rather than deter are needed.  It has also been argued that there is a conflict 
between the dominant medical approach of identifying the ‘chief reason’ for consulting, and 
patients’ experience of minor and indistinct complaints that don’t reach the threshold for 
seeking medical care.68 This may explain the finding that one of the predictors of help-
seeking for potentially malignant oral symptoms was having ‘another reason to consult a 
health professional’; i.e. the oral symptom did not deserve its own consultation.69 Asking 
patients, particularly those from lower SES backgrounds, if there are any other issues they 
would like to ask about (a core PCP consulting skill), could help promote discussion of more 
minor or indistinct complaints that might nonetheless indicate a need for investigation. 
More time may also need to be allocated to discussion with patients about what to do if 
symptoms come back after a negative investigation; the use of ‘safety-netting procedures 
should, in theory, be helpful, and recommendations for primary care have been developed.70 
 
Public awareness campaigns and how they relate to primary care 
Improving symptom awareness in the UK has been tackled largely with public education 
campaigns about specific symptoms; often linked with subtle messaging that the PCP would 
welcome a consultation.  There is clear evidence of increased awareness in response to 
these campaigns,71 and evidence of more visits to the PCP with the target symptoms, 
although the effects may be short-lived. Faced with symptomatic patients, the challenge for 
primary care doctors is to identify those with the highest likelihood of having cancer when 
most patients they see will not have the disease - indeed, the symptoms involved are both 
common and not cancer-specific.  
 
Nowhere do these issues apply more than in the case of lung cancer. Campaigns to promote 
earlier referral of patients suspected of having lung cancer has been the most successful 
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reported to date in terms of achieving significant increases in referrals for chest X-ray and 
specialist assessment, more diagnoses, a stage shift to earlier disease and an increase in 
potentially curative treatment.71,  
The public awareness campaign in England, based on the strapline:  “Been coughing for 
three weeks or more? Tell your doctor” (Fig 2.1) led to a 67% overall increase in patients 
across all age groups visiting their PCP with a cough, though the majority of PCPs surveyed 
were supportive of the campaign.   
 
 
Fig 2.1 Be Clear on Cancer campaign poster 
 
Cancer screening and primary care 
Moving to screening for cancer, primary care has equally important roles - even in the 
context of centrally organised national programmes. There are well-established principles 
for the implementation of national screening programmes which emphasise adequate 
information, and good acceptability and uptake; all within the remit of primary care. In 
Europe the number of countries that are introducing national screening programmes is 
growing. European programmes typically have centrally-organised recruitment and follow-
up, and the three most widely available programmes are for breast, cervical and colorectal 
cancer screening.  The United States tends to do opportunistic screening, but a recent 
review for the CDC emphasised the value of learning from organised cancer screening 
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programmes in other countries.47 One recent issue has been the controversy over breast 
cancer screening72 which has highlighted the need for balanced information.  The role of 
primary care in meeting information needs such as these, and in providing other key 
elements of screening, varies between countries, and is shared to varying degrees with 
screening programme organisers. 
 
In recent years there has been a focus on ‘personalised medicine’ which emphasises the 
need to tailor preventive and treatment strategies to individual patients – taking account of 
information from genomics, family history, lifestyle and other areas. There is, for example, 
growing interest in the concept of risk stratification in cancer screening – that is, designing 
screening strategies based on individual risk, rather than assuming everyone in the target 
population has the same risk. PCPs have potentially important roles in the collection of 
genetic and family history information. Information on family history can help GPs 
personalise health messages – patients typically attach high significance to such 
information.73 It appears, however, that family history information is collected inconsistently 
in primary care settings; while tools have been developed which could add significant family 
health information, few are specific for primary care.74 
 
While limited primary care-based testing for specific genes may emerge in the next few 
years, such information will need to be combined with family history, and a range of 
sociodemographic, behavioural, and environmental risk factors if it is to be useful in risk 
stratification;75 further, the complex ethical issues associated with this kind of information 
will need to be addressed. At present there is little evidence on how such an approach might 
work in practice, but it is vital that primary care actively engages in emerging strategies.  
 
How involved are PCPs in screening? 
Our ‘case study’ is colorectal cancer (CRC) screening. CRC is a leading cause of cancer-related 
mortality in western countries and screening programmes can lead to significant mortality 
reductions or in the case of endoscopic screening, to reductions of incidence as well.  CRC 
screening programmes are typically designed for asymptomatic individuals at average risk, 
50 years of age or higher.  Most CRC screening in Europe is based on the faecal occult blood 
test (FOBT) or the faecal immunochemical test (FIT), with colonoscopy for test-positive 
individuals, although the UK is implementing a national flexible sigmoidoscopy programme 
alongside the FOBT programme.  
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The level of CRC screening development varies in Europe. Screening on a national level has 
been implemented in 20 EU countries and the involvement of PCPs varies according to the 
chosen strategy and local health care policy.  For example, in Germany, the Czech Republic 
and Slovakia, PCPs perform FOB testing in their offices; in Poland they recruit patients for 
colonoscopic screening; in Italy the involvement varies across the country; and in the UK, 
Netherlands, Spain and Finland, PCPs are not directly involved in the provision of the 
programme.76 PCPs also have varying roles in follow-up for test-positive individuals; in some 
countries they are responsible for referral to colonoscopy while in others this is organised by 
the programme itself.  
 
The role of PCPs in CRC screening uptake 
For cancer screening programmes to bring about reductions in mortality, a substantial 
proportion of the population must participate. Organized but opportunistic programmes, 
such as those established in Germany in 1976, or the Czech Republic in 2000, suffer from low 
participation rates.77 There is a clear evidence for the importance of PCPs in the 
implementation of such CRC screening programmes;78-80 with RCT evidence that their 
endorsement of programme-generated screening invitations increases screening uptake.81  
Further, inadequate PCP involvement appears to reduce recruitment in lower SES groups.82 
Educational interventions targeting primary care physicians also appear to be effective in 
improving CRC screening rates,83 although this evidence is less consistent.84 Further research 
is needed to assess newer approaches to promoting uptake, such as IT-based programs, and 
to identify strategies that are balanced, self-sustaining, and affordable.  
 
Informed choice and CRC uptake 
While coverage is a key outcome in screening, there is a growing emphasis on information 
provisions and informed choice, or ‘informed uptake’;85 screening has the potential to cause 
harm, and there is an ethical imperative to provide balanced information on cancer 
screening. An informed choice has been defined as one that is ‘informed, consistent with the 
decision-maker´s values and behaviourally implemented’. Patients sometimes receive 
insufficient or inadequate information about screening, (in areas such as over-diagnosis and 
overtreatment), compromising the informed choice process.86 To ensure equal access to 
screening, information is needed to suit adults from a broad range of literacy levels. Health 
promotion activities in the community may benefit from targeting lower-literacy 
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populations.50 Screening recruitment can be customized for low-uptake groups, such as 
ethnic minorities - screening invitations typically require adaptation; ideally, they should 
address specific language, attitudes, and cultural barriers to participation.50 Again, the PCP is 
ideally placed to undertake these tasks, but there are few such models available in the 
literature. 
 
Conclusion 
PCPs have important roles in primary prevention, screening and patient help-seeking. While 
a body of evidence supporting these roles is emerging, there remains significant unrealised 
potential. Specifically, PCPs need more effective models to incorporate primary prevention 
into their routine practice. While significant progress has been made in facilitating early 
cancer diagnosis in primary care50 we need a better understanding of how primary care 
might best tackle the many factors which contribute to patient-related delay. There are 
educational issues, but the interplay between barriers to consultation and the messages 
patients take away from PCP consultations needs to be better understood. Finally, we need 
great consistency and sharing of ‘best practice’ in the way PCPs are involved in cancer 
screening. 
 
 
 
 
 
 
 
 
 
 
Action points 2 
 
 
 
 
 
 
Primary care needs to move beyond its focus on smoking and alcohol   
in primary prevention, and engage more effectively in initiatives to   
promote physical activity and reduce obesity 
 
•Primary care should prepare itself for the growth in genomic   
information, and how this information can be incorporated with   
lifestyle and other factors in developing individualised preventive   
strategies 
 
•Population-level early diagnosis and screening strategies need to   
fully engage primary care if they are to maximise their potential 
 
25 
 
Part 3: Early Diagnosis in Children, Teenagers, and Young Adults 
 
Cancer is the leading cause of disease-related death among children in high-income 
countries. The prompt and early diagnosis of cancer in children, teenagers and young adults 
(CTYA) has long been of concern to caregivers, physicians, and policymakers. In this section 
we review the impact of prolonged times to diagnosis, common presentations of cancers 
arising in this age period, the role of PCPs in the diagnosis of CTYA malignancies, the 
challenges they face, and possible strategies to meet these challenges. 
 
Diagnostic intervals 
Given the complexity of the pathways leading to cancer diagnosis, an appropriate 
conceptual framework is necessary. Through a systematic review, Walter et al. adapted the 
Andersen Model of Total Patient Delay to the cancer diagnostic pathway (Figure 3.1).6  
 
 
Figure 3.1: Model of Pathways to Treatment 
 
The Model defines key events and intervals, including the appraisal, help-seeking, diagnostic 
and pre-treatment intervals. In addition, contributing factors to time to diagnosis are 
categorized into disease, patient, and health care provider/system factors.  While Walter et 
al. focused on adult malignancies, their model is transferrable to CTYA cancers, though 
specific contributing factors may differ. The diagnostic interval, i.e. the time between the 
first contact with the healthcare system for cancer-related symptoms and the diagnosis, is 
likely to be of greatest interest to PCPs and will be the focus of much of this chapter. 
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Impact of prolonged diagnostic intervals  
The impact of diagnostic interval lengths upon survival among CTYA with cancer is still 
controversial. Several studies have linked prolonged intervals to advanced stage at diagnosis 
and consequently inferior cancer outcomes, particularly in cancers such as retinoblastoma 
and Hodgkin lymphoma.87, 88 Two studies have suggested an adverse effect of longer times 
to diagnosis in childhood leukaemia, though these have predominantly focused on the time 
interval between diagnosis and treatment initiation, and may therefore be confounded by 
the clinical condition of the child at presentation.89, 90  
 
By contrast, other studies have associated prolonged diagnostic intervals with superior 
survival, a counterintuitive finding known as the “waiting time paradox”.91, 92 Two 
explanations for the waiting time paradox have been proposed.  Firstly, aggressive disease 
may be easier to appraise, leading to shorter diagnostic intervals but associated with 
inherent increased mortality.  Secondly, being more ill at presentation may result in quicker 
prioritization and referrals by primary care physicians (i.e. shorter diagnostic intervals) but 
nonetheless result in inferior survival (“sick-quick”). These two mechanisms are of course 
not exclusive. Three systematic reviews all found evidence of the waiting time paradox in 
children, as did recent studies in medulloblastoma, Ewing sarcoma and acute leukemia.93-95 It 
should be noted however that many of the above studies suffer from significant 
methodological limitations.  For example, most studies lacked sufficient power to explore U-
shaped associations between diagnostic interval length and survival, as demonstrated in 
some adult malignancies.96 Finally, the vast majority of studies have relied either on primary 
data from patients or providers, or on chart abstraction of medical records, with consequent 
issues of recall bias or availability. 
 
Much less controversial is the impact of prolonged diagnostic intervals on psychosocial 
outcomes among children with cancer. Long diagnostic intervals are a source of significant 
distress and guilt to patients, caregivers, and indeed PCPs themselves.95 Prolonged 
diagnostic intervals may also result in a loss of confidence in the healthcare system. Thus 
targeting earlier diagnosis among CTYA cancer patients will lead to improved non-survival 
based outcomes, and may additionally improve survival in select malignancies or 
populations. 
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Challenges to diagnosis  
Prompt diagnosis of cancer in CTYA is a significant challenge, made more difficult by both 
disease, patient, caregiver factors. 
 
Disease 
Despite being the leading cause of disease-related death among CTYA in high-income 
countries, cancer is rare, accounting for less than 1% of all cancers. Childhood cancer also 
represents a heterogeneous group of diverse malignancies very different to those seen in 
older age groups more commonly presenting to PCPs. For the average PCP in the UK, 
diagnosing cancer in a child or teenager is a twice-in-a career event and hence 
understandably low on their list of differential diagnoses.  
 
Table 3.1 Paediatric Cancer Incidence Rates  
 
 
CNS – Central nervous system; ICCC – International Classification of Childhood Cancers 
Rates are per 1,000,000 and age-adjusted to the 2000 US standard population. Rates include 
benign and borderline brain tumors.97 
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Presenting symptoms and signs 
Presenting symptoms of childhood cancer may generally be grouped into three categories.  
The first group includes symptoms that are commonly encountered in primary care and 
which rarely signify serious illness or warrant referral, such as fever, abdominal pain, or 
headache.  These symptoms are however also commonly seen in children presenting with 
cancer.  The second group of symptoms are those which are less common in paediatric 
patients, but are still much more likely to have a benign underlying cause (e.g. first afebrile 
seizure, new onset Bells palsy, lymphadenopathy). These symptoms are more likely to 
prompt referral to secondary care for further investigation and management, though this 
may not always be necessary. Finally, there remains a group of symptoms and signs which 
although rare are virtually always pathological, likely to represent malignancy and require 
rapid work up and referral. Examples would include an abdominal mass, proptosis, and 
leukocoria.  
 
In TYA, the changing spectrum of cancers results in variation in presenting symptoms 
compared with children so that lumps or lymphadenopathy, skin changes, fatigue, testicular 
swelling and more specific symptoms associated with early onset carcinomas become more 
prominent. 
 
A UK population-based case-control study investigating the predictive value of symptoms in 
children presenting to primary care reported that cancer ‘alert’ symptoms, as described in 
England’s NICE guidance for urgent referral for suspected cancer, were relatively uncommon 
in children subsequently diagnosed with cancer.98 In the three months prior to diagnosis just 
over a quarter had any alert symptom recorded by their GP. This proportion only rose to a 
third when the preceding year was considered. Alert symptoms were also recorded in those 
without cancer. This, coupled with the rarity of childhood cancer, meant that most individual 
alert symptom had a positive predictive value (PPV) for cancer of 0.05% or less.98 A further 
study from this group, also using electronic UK primary care records, identified twelve 
symptoms that increased the risk of cancer at least tenfold, though with a low absolute risk. 
The PPV for each symptom increased 2-3 fold in patients with three or more attendances for 
the same problem.99 (Table 3.2) Thus repeat visits may represent a cause for heightened 
suspicion among PCPs. 
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Table 3.2. Positive predictive values for childhood cancer of individual symptoms and in 
combination with three or more consultations for any reason in a 3-month period, against a 
background risk of 0.035%.98 
 
 
The role of alert symptoms is also likely to vary by cancer type and the symptom in question. 
In a Danish study of 253 children with cancer using retrospective questionnaires, alert 
symptoms were recorded in only 5% of patients with bone sarcomas compared to 44% of 
those with lymphoma.100 A second study of 550 children analysed the association between 
symptoms and the diagnostic interval. Children with leukaemia were more likely to 
experience a long diagnostic interval when pain was reported and the shortest intervals 
among children with brain tumours were observed when vomiting was present.101 
 
Patient and Caregiver 
Young children are unable to articulate their symptoms or access healthcare independently. 
They are thus reliant on the caregiver’s interpretation of their signs and symptoms, and on 
the caregiver’s own healthcare seeking behaviour. Parental thresholds for consultation vary 
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considerably; many are willing to self manage non-specific symptoms such as tiredness and 
viral-type infections initially, while others attend more frequently.102 Low parental education 
level has been shown to be associated with prolonged diagnostic intervals in children.103 The 
caregiver’s level of concern can influence both the decision to attend and the outcome of 
the consultation. Persuading doctors of the reality and seriousness of their child’s 
symptoms, without themselves recognizing the possibility of cancer, is commonly reported 
by parents.104  
 
Conversely, parents of teenagers and young adults are reliant on their child to report a 
problem. A number of studies report an association between older patient age and 
increased patient and diagnostic intervals that may reflect a young person’s reluctance to 
discuss health concerns with caregivers or doctors, though the use of primary care by 
teenagers and young adults is relatively frequent.105, 106 The most common barriers to help 
seeking in a study of 11-17 year old British children were ‘worry about what the doctor 
might find’ (72%), embarrassment (56%), fear (54%) and ‘not feeling confident to talk about 
symptoms’ (53%). Low levels of awareness of the features of cancer were also reported 
amongst the teenagers, highlighting them as a risk group for delayed diagnosis.107  
 
Part 3 panel 
Barriers to the prompt diagnosis of childhood, teenager and young adult (CTYA) cancers: 
 
Disease-related 
- Rarity of CTYA cancer 
- Heterogeneity of cancers 
- Overlap of many symptoms with those of common, benign conditions 
Patient/Caregiver-related 
- Inability of young children to articulate symptoms 
- Low health seeking behaviour in many teens and adolescents 
- Limited awareness of CTYA cancer among patients and caregivers 
 
 
The role of the primary care physician 
In some health care systems, paediatric primary care is a specific entity, with clinicians 
restricting their practice to children. In others, including the UK and Denmark, the first 
consultation for an ill child is with a PCP, who offers primary care to all ages. As noted 
earlier, such a clinician will encounter a child with cancer rarely – perhaps twice in their 
career, and thus accumulates less practical experience of children’s health. It is unrealistic to 
expect specific education about particular cancers to be of use: diagnosis of possible CTYA 
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cancer will be recognition of the unusual, perhaps supplemented by observation over a short 
period. A small proportion of presentations will be obvious, such as palpable abdominal 
masses, an absent red reflex with retinoblastoma, or clear cerebellar signs with a posterior 
fossa tumour, though most are much more subtle. There is moderate evidence to suggest 
that primary care summation of the total risk of serious disease in febrile children is more 
than just the simple addition of specific risk markers.108 This extra component, sometimes 
labeled ‘intuition,’ has not been shown in paediatric cancer, but probably exists. In adults, 
PCPs have moderate ability to discriminate malignant enlargement from benign 
enlargement in both cervical lymphadenopathy109 and prostate masses.110 It is likely such 
skills translate to paediatric practice. An overall malignant probability of 0.5% for 
lymphadenopathy in someone aged 16-24 is almost certainly much higher if it has particular 
features suggesting a cancer diagnosis (e.g hard consistency, large size, accompanying 
symptoms of fever, weight loss or night sweats).111 Similarly, fatigue, pallor and bruising 
have very low absolute risks – but when supplemented by repeated consultations or 
parental anxiety probably carry sufficiently high risks to warrant venepuncture.  
 
One potential advance involves electronic clinical decision support. It is possible to integrate 
diagnostic software into primary care clinical computers that automatically searches the 
records for relevant entries and computes an absolute risk of current cancer. This is a reality 
in adult cancer in the UK, and is discussed in detail in the Part 4, though a definitive trial has 
yet to be performed. In CTYA, repeated attendances are a clear marker of risk, and could be 
incorporated into the algorithm. Selection of the specific risk threshold  for prompting the 
clinician to the possibility of cancer will, however, be difficult as absolute risks will be small, 
and ‘prompt fatigue’ a real possibility.  The ‘real world’ utility of electronic clinical decision 
support algorithms in facilitating early cancer diagnosis in CTYA remains to be elucidated. 
 
Finally, the PCP may play a role in the initial work-up of a child with a suspected malignancy.  
On occasion, a PCP can institute testing – such as plain X-ray for bone sarcoma or ultrasound 
for soft tissue masses. Leukaemia is usually obvious on a full blood count. Easy and timely 
PCP access to these simple diagnostic tests is therefore important. However, these are the 
exceptions, and most children with possible cancer will need access to specialist 
investigations. Organisation of such services needs to accommodate two opposing 
principles: first, most children will ultimately not have cancer and second, the few who do 
have cancer will benefit from rapid diagnosis. Arguably, the second of these principles is the 
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more important, particularly when some of the referred children will have alternative, albeit 
benign, diagnoses, which may also benefit from swift identification. Most of the specialized 
investigations require imaging, supplemented by biopsy if necessary. This argues for either 
moderately large specialist paediatric practices or strong referral systems. Treatment of 
CTYA cancer is highly specialized and generally concentrated in tertiary referral centres – 
diagnosis rarely requires this level of specialization. Some countries have established 
guidance for selection of patients for investigation of possible cancer. These have mostly 
been based on secondary care studies, which have limited applicability to primary care.  In 
the UK, NICE criteria for urgent referral for suspected CTYA cancer has been shown to have 
very low absolute risks. Even so, patients value investigation of cancer, even when the 
likelihood is very low112 and the same is likely to be true of CTYA. 
 
Impact of healthcare system factors 
Healthcare system-level factors may impact upon the likelihood of prompt diagnosis in 
several ways.  Given the diagnostic significance of multiple consultations and of detecting 
persistent or worsening symptoms in the child with an underlying cancer, continuity of care 
is important in minimising diagnostic intervals.  Both relational and informational continuity 
are being threatened as the demand for primary health care increases. 
 
Second, even when suspicious of a possible malignant aetiology, PCPs are highly unlikely to 
be able to initiate definitive diagnostic procedures, as noted above.  Healthcare systems with 
defined and rapid referral mechanisms between PCPs and specialty paediatric facilities are 
therefore more likely to facilitate prompt diagnoses. This may be of particular importance in 
the TYA population, whose care in many jurisdictions is dispersed across paediatric and adult 
care settings. 
 
Conclusions 
An early diagnosis of cancer in CTYA will generally decrease parental guilt, increase caregiver 
confidence in the healthcare system, may decrease stage at presentation in some 
malignancies, and even improve long-term outcomes. Significant challenges exist in 
recognising and diagnosing childhood and TYA cancer in the primary care setting and in 
designing the optimal referral service. Despite these challenges, the crucial role PCPs play in 
ensuring prompt diagnosis can be supported through clinical strategies, potentially including 
electronic decision support, accessible primary care and strong referral systems.
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Action points 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prompt diagnosis of cancer in CTYA will need new and 
innovative assessment pathways and tools 
Alternative models of access for patients to diagnostics and 
assessment should be piloted. 
Rapid and robust referral mechanisms from primary care to 
specialist facilities should be developed, particularly for the 
TYA population.   
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Part 4: Early Diagnosis in Adults  
 
Even for cancers for which screening programmes exist, the great majority of cases present 
symptomatically in primary care. Most patients with symptoms that could signal cancer 
much more commonly have a benign cause. PCPs must assess the probability of cancer in 
these patients, their need for referral for further investigations, and the urgency with which 
referral and investigation should be conducted. The conceptual framework (Pathways to 
Treatment) within which diagnosis of cancer should be considered was described in the 
preceding section, while the stages that go to make up the total time from first presentation 
to diagnosis and treatment appear in the introduction to this Commission.  
 
There is growing evidence for several cancers that earlier diagnosis of symptomatic cancer is 
associated with improved clinical outcomes.113 Further, prompt diagnosis is associated with 
better patient experience of subsequent cancer care, particularly those aspects delivered in 
primary care.114Preventing avoidable delays in primary care by accurate assessment of the 
likelihood of cancer, and expediting the diagnosis, could therefore contribute to 
improvements in cancer survival.  
 
The diagnostic process in primary care  
PCPs are confronted with a wide spectrum of complaints and symptoms in their daily 
consultations; the most prevalent being respiratory, musculoskeletal and gastro-intestinal. In 
the majority of patients the prognosis of these symptoms is favourable, and the complaints 
are self-limiting. Given this good prognosis a single consultation is sufficient for most 
patients, and in only 5-15% is additional diagnostic testing required.115    
 
Clinical decision making in primary care is primarily directed by prognosis rather than 
diagnosis, and is based on risk estimation. The overall aim is to identify in a timely way those 
patients with a high risk of serious disease, as they need early additional diagnostic tests and 
therapeutic interventions.116 To prioritize among the many potential differential diagnoses 
GPs use hypothetico-deductive methods or pattern recognition strategies, matching the 
presenting symptoms to their knowledge and clinical experience.117 Diagnostic reasoning in 
primary care generally follows a Bayesian approach, one of the cornerstones of evidence 
based medicine. The baseline risk of the patient is determined by pre-set individual 
characteristics, such as age, gender and family history, which is added to the baseline 
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population risk (prior risk or incidence in the primary care population). In a stepwise 
diagnostic process this risk profile is further detailed. The presence or absence of each 
individual symptom and physical sign makes the target disease more or less likely. This 
results in an integrated diagnostic model that estimates the individual risk of disease 
(posterior risk), and forms the basis of further management.   
 
If the risk of serious disease is low, no further action is required and a watchful waiting 
policy can be applied. If the risk is high, further action is required, usually specialist referral. 
In case of intermediate risk118 additional diagnostic testing can up- or downgrade the risk to 
a level that facilitates further management by the PCP. In the case of high stake diagnoses 
such as cancer the need for an adequate diagnostic process is high, and the level of risk 
triggering investigation or referral is lower. This implies that in the case of cancer suspicion 
the threshold for additional testing and referral is usually lower. Although PCPs do not 
explicitly think about their diagnostic reasoning in this way,119 and particularly not in relation 
to specific numerical risk thresholds, this is the basis for most diagnostic reasoning in 
primary care.  
 
Several factors modulate this diagnostic process. PCPs are aware of the delicate balance 
between the potential benefit and harm of additional diagnostic testing, especially in 
systems where they play a strong gatekeeping role.  Patients with serious disease need an 
adequate and timely diagnosis, but irrational use of diagnostic testing in low risk patients 
may result in incidental diagnoses, stress for the patient and societal costs. Continuity of 
care is a cornerstone of good general practice. The longstanding relationship with a patient 
provides the PCP with valuable additional information about the medical and psychosocial 
history which may alter the prior risk of disease.  Furthermore, acquaintance with the 
patient and their preferences about healthcare may modify the thresholds in the decision 
making process, making the PCP accept different risk thresholds between patients before 
further diagnostic testing. Continuity of care can have negative impacts on timely cancer 
diagnosis by altering patients’ help-seeking behaviours and potentially making doctors 
complacent about their symptoms, especially if they are frequent attenders.120 However, the 
impact of doctor – patient continuity on time to diagnosis appears to be small (a maximum 
of 7 days for colorectal cancer) and not clinically important.121 Finally, presumed life 
expectancy also affects different steps in the diagnostic process, as PCPs take the benefit of 
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an early diagnosis into account in their decision for additional testing and referral for people 
who may be close to death.  
 
PCPs face several challenges in accurately diagnosing cancer. First of all, symptoms are 
common, but cancer is rare. PCPs in the Netherlands may see 20-30 patients every day, but 
in an average year will only diagnose one patient with colorectal cancer, one with prostate 
cancer and one with lung cancer. Many will only see one or two patients with rare cancers, 
such as myeloma or glioma, in their entire career. Given the low prevalence the prior risk of 
cancer in primary care is usually low, which limits the predictive value of signs and 
symptoms and of diagnostic tests.  Secondly, the presentation of cancer in primary care is 
often non-specific, especially in the early stage, and isolated symptoms are usually poor 
predictors. Common symptoms like cough, abdominal pain and fatigue are present in most 
patients with lung or gastro-intestinal cancer, but the large majority of patients presenting 
with these symptoms do not have cancer. In some patients adequate diagnosis requires time 
for symptoms to evolve.122 Finally the presentation of cancer may be obscured by factors 
that hamper timely diagnosis such as co-morbidity. Existing respiratory disease can prolong 
the diagnosis of lung cancer11, and a high burden of psychiatric or psychosocial comorbidity 
is associated with delayed diagnosis of colorectal cancer.123      
 
Panel Part 4 
 Most cancers present symptomatically in primary care but the symptoms that could 
signal cancer more commonly have a benign cause. 
 Advances in the epidemiology of cancer symptoms in primary care allow more 
accurate risk assessment and selection of patients who require urgent 
investigationRisk assessment tools could potentially improve early diagnosis of many 
cancers in primary care but trials are needed to confirm this. If these trials 
demonstrate efficacy, implementation of risk assessment tools through primary care 
clinical software systems would be justified. 
 Certain cancers may be inherently more difficult to diagnose in primary care and will 
require the development of accurate biomarkers to support early diagnosis 
 
Epidemiology of cancer symptoms in primary care 
Accurate diagnostic reasoning in primary care requires an understanding of how well 
symptoms predict risk of a cancer diagnosis. In the last ten years the evidence-base around 
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the epidemiology of symptoms, signs and diagnostic tests associated with cancer in primary 
care has improved, with a variety of studies addressing the issue of early detection and 
diagnosis. Each epidemiological study has strengths and weaknesses, and provides different 
but complementary information that can help improve the diagnostic accuracy of cancer in 
primary care.124  
 
Case-control studies, exemplified by the Cancer Prediction in Exeter (CAPER) series of 
studies, into colorectal, lung, prostate, brain and ovarian cancer have made major 
contributions to this evidence base.125  This methodological approach using large primary 
care databases has been extended to cover 16 cancers. The strength of this approach is that 
the positive predictive value of individual symptoms, signs and diagnostic tests associated 
with these cancers are determined. The shortcomings include the nature of the case-control 
study design, including recall bias in terms of recorded symptoms and spectrum bias 
because of inability to include the totality of the control population who did not develop 
cancer. 
 
Prospective studies also using large primary care databases, alongside case-control studies, 
have been used to develop and validate algorithms that estimate absolute risks of different 
types of cancers in men and women incorporating multiple symptoms and risk factors.126, 127 
This approach allows the independent effects of several clinically important factors to be 
estimated: higher risk symptoms that include weight loss, abdominal pain, indigestion, 
dysphagia, abnormal bleeding, lumps; general “non-specific” symptoms such as tiredness, 
constipation; and risk factors such as age, family history, smoking status, alcohol intake, 
deprivation, body mass index, and current medical conditions. Regression analysis enables 
the development of a risk equation for an overall risk of cancer, based on the combined 
elements of different cancers. The QCancer web tool applies these models to estimate the 
risk of patients having current but as yet undiagnosed cancer, taking account of their risk 
factors and current symptoms.128 The strengths of this approach include the large, 
representative sample, duration of follow-up, and lack of selection, recall and responder 
bias. Shortcomings include a lack of formally adjudicated outcomes such as cancer diagnosis, 
potential information bias (greater information collected for patients with a diagnosis of 
cancer), and missing data in relation to symptoms, signs and diagnostic tests, particularly in 
those patients without a cancer diagnosis. Other large databases have taken a different, but 
complementary approach, examining the association of alarm symptoms (first occurrence of 
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haematuria, haemoptysis, dysphagia and rectal bleeding) with cancer. This approach enables 
a more accurate quantification of cancer risk with classical presentation129 but many patients 
with cancer in primary care do not necessarily present initially with classical features.  
 
Several smaller, prospective observational studies of individual risk of cancers, particularly 
colorectal, breast, lung and melanoma have been published. They also adopt a multivariable 
approach, estimating the probability of a target cancer based on a combination of 
independent predictors of symptoms, signs and available diagnostic tests. The strength of 
this approach is that all relevant predictors are included, irrespective of cancer outcome, 
thus ascertainment of both symptoms and outcomes is high. A brief overview of the current 
evidence-base for common cancers includes the following studies: 
 
Colorectal cancer 
Systematic reviews of prospective observational studies have confirmed the diagnostic value 
of well-recognised symptoms and signs, including rectal bleeding, abdominal pain, appetite 
loss, alteration in bowel habit and weight loss. These independent effects have greater 
diagnostic yield when present in combination. The prior probability of colorectal cancer in 
patients presenting to their GP in primary care ranged between 3.3-15.4% in eight 
community based studies130, so even when a patient presents with a full complement of 
symptoms and signs, the probability of colorectal cancer remains modest, approximately 20-
25%. This means that further diagnostic testing is always needed.130 Further research from 
the QCancer (Colorectal) study shows the importance of determining anaemia in a patient 
presenting with rectal bleeding in terms of additional diagnostic yield.131  
 
Breast cancer 
Breast symptoms are a relatively common reason for encounter in primary care. Prospective 
studies have shown that the probability of breast cancer is relatively low amongst women 
presenting with breast symptoms, in the region of 3%. Symptoms and signs associated with 
increased probability of breast cancer include increasing age, presence of a discrete lump, a 
lump ≥2cm, thickening of the breast, lymphadenopathy and tethering to the skin or chest 
wall. This clinical prediction rule has been found to perform well in the context of patients 
referred to a breast care clinic but validation in a primary care population is needed.132  
 
Lung cancer 
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The QCancer (Lung) study shows that independent predictors include haemoptysis, appetite 
loss, weight loss, presence of cough, smoking and history of chronic obstructive airways 
disease as well as increased  body mass index and higher deprivation.133 The challenges of 
diagnosing lung cancer and its associated symptoms are discussed further below.  
 
Melanoma 
The weighted seven point checklist includes the following features: change in size of lesion, 
irregular pigmentation, irregular border, inflammation, itch or altered sensation, size >7mm 
and oozing or crusting of the lesion. A recent validation study in English primary care 
suggests a cut-off score of four performs best at identifying clinically suspicious pigmented 
skin lesions.134 
 
Difficult diagnoses and rarer cancers 
Cancer is, of course, not a single disease, rather a heterogeneous collection of different 
diseases. These all manifest in different ways, and this accounts for why some are harder, 
and some easier, to diagnose in primary care. There is an emerging literature on this, and a 
number of metrics that can be compared between cancers to determine the harder to 
diagnose cancers. These include the number of pre-referral consultations,135 various 
measures of time interval, for example the primary care interval and the diagnostic interval5, 
and route to diagnosis (routine, urgent or emergency referral).8  
 
Lyratzopoulos and colleagues have classified cancers into one of three groups based upon 
ease of diagnosis.10 Those categorised as easier to suspect, because of more obvious 
symptoms, include breast, melanoma, endometrial and bladder. Those categorised as 
intermediate cancers include colon, renal and lymphoma. Those categorised as harder to 
suspect cancers include myeloma, pancreas, stomach and lung. These harder to suspect 
cancers are typified by non-specific presenting symptoms. Additionally, but not exclusively, 
they may be some of the rarer cancers. The median diagnostic intervals (time from first 
presentation in primary care to diagnosis for these cancers) in a large English study were: 
lung 112 days; myeloma 156 days; stomach 89 days; and pancreas 56 days.136 We consider 
each of these in turn, examining specific reasons why they are difficult to diagnose, leading 
to practical recommendations to improve their diagnosis. 
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Whilst one of the commoner cancers, lung cancer remains one of the harder to diagnose, 
and can be easily missed. The diagnostic difficulty stems from the lack of a clear ‘symptom 
signature’,137, the presence of pre-existing lung disease causing similar symptoms, non-
respiratory presenting symptoms, atypical symptoms and patient-mediated factors.138 False 
negative tests are an important factor in delayed cancer diagnosis generally, but they are 
common in lung cancer. In two case series initial chest x-rays were normal in 20-25% of 
people subsequently diagnosed with lung cancer.139 Improving direct access to CT scans 
could reduce the risks from false negative investigations in people with suspected lung 
cancer. The positive predictive values (PPVs) of lung cancer symptoms in primary care are 
generally low but higher with current smoking, multiple and persistent symptoms and age. 
The symptom with the highest PPV is haemoptysis, although this is an infrequently 
experienced symptom.11  
 
There is a much smaller evidence base regarding the other three ‘difficult to diagnose’ 
cancers. Myeloma is one of the rarer cancers and an average PCP in the UK will only see only 
one new case every 8-10 years. The presenting symptoms all have low PPVs,140 meaning that 
many cases are not diagnosed until irreversible organ damage has occurred. Symptom onset 
may be gradual, and may be attributed to ageing. For stomach cancer, the PPVs of 
symptoms are all relatively low, especially in younger people.126 Intra-abdominal solid 
tumours tend to cause varied symptoms which are more usually associated with benign 
causes. More predictive symptoms, for example bleeding, only tend to be present when the 
disease is more advanced. For pancreatic cancer, the PPVs of symptoms are all low, at least 
until advanced disease is present, often indicated by jaundice, by which time the suspicion 
of a pancreatic cancer diagnosis is easier.  
 
What can be done to facilitate the diagnosis of ‘harder to diagnose’ cancers, such as those 
described above? The principles of good medical practice are paramount. They include; a 
thorough history and examination; adherence to referral guidelines; safety-netting;71, 138 and 
the use of diagnostic tests. The greater use of currently available investigations has also 
been advocated by others,10 but this must not be to the detriment of urgent specialist 
referral where this is mandated, as use of PCP-initiated investigations is associated with 
longer time to referral for a range of common cancers.141 
41 
 
Risk assessment tools and decision support 
One approach advocated, particularly for cancers which are more difficult to diagnose, is the 
use of decision support interventions in primary care practice.10 This is based on systematic 
review evidence that decision support systems can improve clinician performance and 
diagnostic test ordering.142, 143 The development of risk models which predict likelihood of an 
undiagnosed cancer has led to the creation of risk assessment tools to implement these risk 
models into general practice. The largest implementation projects have been in the UK of 
tools implementing either the CAPER or QCancer risk models. In one evaluation, paper 
versions of the CAPER charts for lung and colorectal cancer were provided to 165 general 
practices in England and cancer referral data were compared for 6 months before and after 
introduction of the risk tool.143 They were associated with an increase in referrals for 
investigation and urgent cancer clinics, and an increase in lung and colorectal cancer 
diagnoses.  
 
 
Figure 4.1. Positive predictive values (%) for colorectal cancer for individual features, repeat 
presentations and for pairs of features (in the context of a background risk of 0.25%).125 
 
 
Electronic risk assessment tools which implement the CAPER and QCancer risk models and 
integrate them into the primary care practice electronic medical record have now been 
developed and are being piloted in England.145 PCPs can enter a patient’s symptoms into the 
tool and calculate cancer risk, and are prompted to consider a cancer diagnosis if there is 
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prior risk of cancer >2% when a patient presents. The risk tool can also audit the whole 
practice population to identify those at higher risk of undiagnosed cancer who might benefit 
from further assessment. There are significant challenges to implementing these types of 
tool into general practice. PCPs express concerns about using these tools within the 
consultation while those with long experience are more likely to trust their intuition than the 
estimated risk score.146  
 
Several randomised controlled trials of risk assessment tools are in progress which should 
provide more robust evidence about their impact on clinical decision-making and diagnostic 
delay. At present, however, their clinical and cost-effectiveness is unknown. Further work is 
also required to understand how best to implement these types of tool into routine practice.  
 
Conclusions 
There is increasing interest in the early diagnosis of cancer and the critical contribution of 
primary care in reducing diagnostic delay. However, uncertainties remain, including the 
most appropriate risk threshold for referral to secondary care. This is a key question as 
guidelines for urgent referral for suspected cancer are increasingly adopted and electronic 
tools are implemented which provide estimates of risk of undiagnosed cancer. Current 
thresholds range from 2% risk upwards,124 but low thresholds are likely to increase the 
burden of low risk patients being referred to specialist diagnostic services, with attendant 
costs in terms of psychological damage to patients and opportunity costs to the health 
service. PCPs may become more risk averse and lower their thresholds anyway, in response 
to the public and political discourse around diagnostic delay.  
 
Improved understanding of the symptomatology and development of risk models and tools 
may be of use for some cancers but whether they will help with the most difficult cancers to 
diagnose remains to be seen.  Earlier diagnosis of these could depend on the identification 
of accurate biomarkers that could be used in specific populations at higher baseline cancer 
risk. Until then, heightened awareness of key symptoms and signs and application of best 
epidemiological evidence on how they predict cancer risk, remain at the heart of early 
diagnosis of cancer in primary care.   
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Action Points 4 
   Internationally, evidence for the epidemiology of symptoms 
should be systematically applied to inform diagnostic pathways 
aimed at reducing time to cancer diagnosis. 
 If research currently under way confirms the utility of electronic 
clinical decision support, such tools should be rapidly 
incorporated into the clinical software used by PCPs 
 Effective biomarkers for early diagnosis, both in symptomatic 
patients and in those with a higher baseline risk, are a research 
priority 
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Part 5: Cancer Survivorship Care 
 
The number of cancer survivors is increasing rapidly, largely as a result of improvements in 
cancer outcomes due to improvements in screening, early diagnosis and treatments for cancer, 
coupled with more cases as a result of an ageing population.  In the UK, for example, it is 
estimated there are approximately two million cancer survivors currently, around 3% of the 
population, predicted to rise to four million by 20304, . Traditional models of follow-up where 
patients continue to attend hospital out-patient clinics typically for three to five years, or 
sometimes much longer, are no longer sustainable. More comprehensive approaches to 
follow-up are required that meet the range of needs that cancer survivors can have.  The 
consequences of cancer and its treatment put cancer survivors at increased risk for morbidity 
and mortality, and reduced quality of life.  The role of PCPs in the survivorship phase is not well 
defined, and yet with their knowledge of the patient’s prior medical history, co-morbidities 
and family situation, and their holistic approach to care, PCPs have much to offer. The purpose 
of this section is to consider the role of primary care in optimising the provision of cancer 
survivorship care.   
 
Long term and late effects of treatment 
The consequences of cancer and its treatment can have a wide range of adverse effects, 
including physical, psychological, social and financial, on both patients and their families. 
Effective management of these consequences is central to good survivorship care. In terms of 
physical effects, some damage to normal tissues during treatment is inevitable, with the 
impact on quality of life varying with the type of treatment. Whilst some treatment effects can 
be relatively short term, for a significant minority of patients problems following treatment can 
persist and become ‘long-term effects’.147 Examples include urinary, gastro-intestinal, sexual 
functioning problems following treatment for pelvic cancers; lymphoedema and menopausal 
symptoms following breast cancer treatment.  In addition, some problems do not arise until 
months or even years after the end of treatment - referred to as ‘late effects’.  Examples 
include the development of osteoporosis following endocrine therapies,148 heart disease 
following certain types of chemotherapy or radiotherapy,149 and the development of second 
cancers.150  Studies of childhood and young adult cancer survivors have  helped quantify the 
risk of long-term and late effects and have shown, for example, that patients who were treated 
when young with radiotherapy or chemotherapy for Hodgkin lymphoma, Non-Hodgkin 
lymphoma, or testicular cancer have an approximately four fold-increased risk of developing a 
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new malignancy,  and over a five-fold increased risk of developing congestive heart failure,  
typically occurring more than 10 years after treatment.151-153  Less is known about the 
magnitude of the risks following treatment for cancer as an adult, and most research to date 
has been performed in selected populations of patients recruited in secondary care.   This is an 
important area of future research, and it is hoped that genetic profiling may be useful for 
predicting those at greatest risk of late effects.154  The PCP and other members of the primary 
care team have a potentially important role to play.  Indeed, increased contact rates with the 
PCP have been observed following a cancer diagnosis for help with both treatment-related 
side effects and psychological problems155, 156 and, as patients have often been discharged 
from secondary care when they develop late effects, the majority will first report symptoms to 
the PCP. In addition, many patients with cancer are elderly with co-morbidities and are best 
placed to provide them with holistic care. Guidelines have been produced for the management 
of long-term and late effects of cancer therapy in survivors of childhood cancer (e.g. 
www.survivorshipguidelines.org  or www.nccn.org)  and are beginning to be developed for 
adults with cancer.157 Although some guidelines make specific reference to primary care158, 
however, in many instances no formal role is described for the PCP during either the treatment 
or survivorship phases. At present, many PCPs will lack awareness of the range and scale of 
potential treatment effects that cancer survivors may experience.159 Education is required to 
ensure they have the necessary information and skills to: assess patients, offer support and 
advice; refer back to secondary care or signpost to other services as appropriate e.g. 
counselling, financial and social support; and to be aware of the possibility of a second cancer 
or cardiovascular problems at a younger age than one would generally expect.160     
Psychosocial Impact 
Studies from the psychosocial oncology literature have consistently found that around 25-30% 
of cancer patients develop some form of psychological disorder across the trajectory of cancer, 
including the survivorship phase.161  Adjustment and post-traumatic stress disorders, 
depression and anxiety are the most common clinical conditions observed, with higher rates 
than seen in the general population. Fear of recurrence, body image consciousness 162 
concerns about sexuality and fertility, stigmatization and discrimination, altered social 
relationships and problems in return to work and in re-assimilating with social groups, and 
negative feelings (mistrust toward body, anger, and guilt) have been reported as common 
concerns in cancer survivors seen in different clinical contexts,163  including primary care 
services.164 
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For these reasons, screening for and monitoring s, are an important part of clinical practice for 
both oncologists and PCPs.165 Risk factors for psychological disorders such as a history of 
psychiatric illness, poor social support, personality factors (e.g. negative affectivity and social 
introversion), stressful life events, and should also be regularly assessed in the clinical 
encounter by oncologists and PCPs.  
 
Consideration of the impact of cancer on the family is also important, since cancer 
reverberates in the family system with potential negative consequences on spouses and other 
family members. Exploring the family needs across the trajectory of cancer and cancer 
survivorship and identifying adaptive, functional and non-adaptive family coping mechanisms, 
as well as family structure and level of functioning (cohesive versus conflicting or disruptive 
families) is all extremely important. Empirical studies demonstrate that, irrespective of gender, 
age,  ethnicity, and stage of the disease, 25-35% of caregivers develop symptoms of emotional 
distress, and to a lesser extent (15%) depression, with repercussions on quality of life and 
physical health.166 Psychopharmacological167 and psychological interventions, in their many 
possible formats (e.g. individual, couple, family, or group therapy) and models (e.g. cognitive-
behavioural, relational, psychodynamic)168  therefore represent a specific part of an 
interdisciplinary approach to cancer survivorship, including primary care, in order to properly 
respond to psychosocial needs, and reduce the levels of emotional stress and increase coping 
efficacy among cancer survivors.    
 
Detecting recurrence 
Detection of recurrence is also central to survivorship care. Recurrences can either be detected 
by proactive surveillance testing, or following presentation with clinical signs and symptoms. 
The goals of surveillance are to improve outcomes; ‘salvage’ the disease and cure it, or at the 
very least institute palliative therapy earlier to either improve survival and/or quality of life. 
These benefits must be weighed against potential harms, such as the anxiety and stress caused 
by false positive testing, complications of subsequent invasive procedures (biopsies, radiation 
from imaging), and costs. 169 
  
The essential components of surveillance are generally considered to be 1) history and physical 
examination to detect symptoms and signs that could portend recurrence, 2) examination of 
the primary site (e.g., mammography for breast cancer, endoscopy for colorectal cancer), 3) 
tumour markers (CEA for colorectal cancer, PSA for prostate cancer), and 4) imaging for distant 
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recurrence.170 Evaluation of the primary site also serves to identify second cancers, as genetic 
predisposition or environmental exposures responsible for the original diagnosis, or 
treatments like radiotherapy, often leave patients at increased risk for another.171 
Regarding the history and physical examination, while any persistent new symptom usually 
merits investigation, clinical evaluation should be particularly focused on recognizing the 
symptoms and signs in the relatively few clinical situations where early detection of 
recurrences can improve outcomes.172, 173 Often this consists of pain or some other 
abnormality at the primary site for a local recurrence. For cancers where a limited number of 
metastases (‘oligometastases’) could potentially be resected for cure, right upper quadrant 
abdominal pain may suggest liver metastases, while a persistent dry cough could signify lung 
metastases. Constitutional symptoms such as fatigue, anorexia, and weight loss may suggest 
metastatic disease, but are non-specific.174 It is also important that patients are well-informed 
about the potential signs and symptoms of recurrence. 
 
Unfortunately, most metastatic cancers cannot be cured, and in most cases early treatment of 
asymptomatic incurable disease has not been shown to improve outcomes. This is why routine 
testing for metastases from breast cancer, for example, has been shown to provide no benefit 
in randomized trials and is not recommended.175 Even potentially curable hematologic 
malignancies are not clearly benefitted by aggressive surveillance. For example, by the time 
recurrent lymphoma is detectable by imaging studies, a combination of symptoms, signs, and 
lactate dehydrogenase measurement would also have picked up almost all lymphoma 
relapses.176 In fact, there are actually relatively few situations where specific surveillance 
testing has been shown to be beneficial (Table 5.1). Consequently, most guidelines (e.g., 
www.nccn.org) recommend clinical evaluation with further testing only as clinically indicated. 
Notable exceptions include colorectal cancer,177 some sarcomas,178 and kidney cancers,179 
where a minority of patients with oligometastases to the liver or lungs can be cured surgically, 
and testicular cancer  and Hodgkin’s disease,180 which can be salvaged with aggressive 
chemotherapy. In these situations, testing with tumour markers and imaging to detect 
recurrences earlier, as opposed to simple symptomatic follow up, makes sense, and in some 
cases such as colorectal cancer, high level evidence  has shown improvements.181  
 
 
 
 
 
48 
 
Table 5.1: Routine surveillance tests in patients with no symptoms or signs that have a 
rationale and/or evidence base for improving outcomes 
Cancer Tests 
Anal  Anoscopy 
Bladder cancer  Urine cytology, cystoscopy and/or urinary tract imaging 
Breast  Mammography 
Cervical  Cervical/vaginal cytology 
Colorectal  Endoscopy 
 Tumor marker: CEA 
 Chest, abdomen (& pelvis for rectal) imaging 
Head and neck  Endoscopy or imaging if necessary to examine the 
primary site 
Hodgkin’s 
Disease 
 Chest, abdomen, pelvis imaging 
Kidney  Chest and abdominal imaging  
Leukemias  Complete Blood Count 
 Bone marrow assessment in some (e.g., ALL, CML) 
Prostate cancer  Tumor marker: PSA 
Sarcomas  Imaging of the primary site if necessary  
 Chest imaging 
Testicular  Tumor markers: AFP, BHCG 
 Chest, abdomen, pelvis imaging 
 
Prevention 
Research into the effects of nutrition and physical activity in cancer survivors is still in its early 
stages. There is some evidence that addressing exercise and diet can lead to improvements in 
the quality of life in cancer survivors.  There is also a growing body of evidence in relation to 
the potential to reduce the risk of recurrence and mortality in some cancer types.  The 
evidence is strongest in relation to exercise and breast cancer, where a recent systematic 
review of cohort studies found that increasing levels of physical activity post-diagnosis was 
associated with up to a 34% (95%CI=16–38%) decreased risk of breast cancer mortality.182  In 
colorectal cancer and prostate cancer there is also some evidence to suggest physical activity 
may decrease mortality, 183, 184 although more evidence is needed.   However, physical activity 
also improves heart health and can reduce the risk of osteoporosis, and may be helpful in 
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limiting the cardio-toxic and other long term effects of some cancer treatments.  Levels of 
physical activity in cancer survivors are not high185 and primary care services can play an 
important role in advising on the potential benefits of exercise and actively encouraging 
participation, for example through exercise prescription.   
 
Evidence on the effectiveness of specific dietary interventions in cancer survivors in reducing 
the risk of recurrence is still developing.  There is growing evidence of the importance of 
maintaining a healthy BMI, but further evidence is required before specific guidance in this 
area is warranted.  For now, the World Cancer Research Fund recommends cancer survivors 
follows guidance for reducing the risk of primary cancers.186 
 
 
Part 5 Panel 
Key cancer survivorship issues 
 There are increasing numbers of cancer survivors with a range of physical and 
psychosocial needs 
 As knowledge increases regarding the potential long term and late effects of cancer 
diagnosis and treatment, methods for optimising survivorship care are needed 
 Primary care, with its holistic approach, has a potentially important role in cancer 
survivorship care.  At present, this is poorly defined. 
 Evidence suggests primary care based and shared care models of follow-up can be 
just as effective as secondary care led follow-up for breast and colon cancer.  Good 
communication between all care providers and clear guidance for primary care 
professionals is key. 
 
Models for delivering survivorship care   
With the increasing numbers of cancer survivors and consequent demands on secondary care, 
there is growing interest in the potential for primary care to play a greater role in survivorship 
care. Studies have shown willingness from PCPs and support from secondary care for greater 
primary care involvement in follow up, provided there is the provision of adequate guidelines, 
educational support (knowledge and skills), clear lines of communication with easy access back 
into secondary (hospital) care, robust monitoring systems in place in primary care and 
adequate resourcing.187, 188 Patients recognise the potential benefits in terms of convenience, 
familiarity, knowledge of co-morbidities and family situation offered by primary care, but have 
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also expressed concerns about PCPs having the required level of knowledge.188.  Some gain 
considerable reassurance from on-going hospital follow-up, although it has been 
acknowledged that patients are not well-informed about the evidence for the benefits of 
conventional follow-up appointments this may alter if the evidence for the benefits of follow-
up was better understood.189  
 
To promote communication between all providers of cancer care (secondary and primary care) 
and the patient, survivorship care plans were recommended by the Institute of Medicine (IOM) 
in its 2005 report From cancer patient to cancer survivor:  Lost in transition.190 These plans 
were intended to make it explicit what the diagnosis was, treatment received, and specific 
recommendations for care going forward. The latter includes surveillance for recurrence, 
reminders to not ignore any non-cancer comorbidities and other screenings and preventive 
health maintenance, and guidance around common survivorship issues like long-term and late 
effects, psychosocial concerns, employment, and insurance challenges. The plan would also 
identify which specific provider was responsible for which aspect of survivorship care.  
Although there is general agreement that survivorship care plans would be desirable, their 
uptake in the US and elsewhere has been slow.191 This is largely because oncology providers 
have had difficulty incorporating their creation into routine workflow, mainly because of the 
time required. Moreover, randomized trials of survivorship care plans have been unable to 
detect an improvement in outcomes.192-194 Recognizing these challenges, efforts have recently 
focused on identifying the essential elements necessary for communication and care.195 The 
actual form the plan takes is a secondary consideration. Informal communication is preferable 
to no communication. Survivorship care planning must be tailored to accommodate the 
specific needs and capabilities of all involved. 
 
PCPs now play a large role in managing the on-going care of patients with complex health 
conditions such as diabetes, coronary artery disease and COPD – and some advocate that 
cancer follow-up care could similarly be shifted to primary care for certain cancers and for ‘low 
risk’ individuals.  Others favour an integrated or shared care approach with a level of hospital 
contact maintained at least for the first period of survivorship.  Two trials comparing primary 
and secondary care follow up for breast cancer196, 197 and one for colorectal cancer198 suggest 
no differences in quality of life, patient satisfaction or clinical outcomes (recurrence and 
survival). Similarly, studies of integrated models of cancer follow up point to improved patient 
satisfaction and cost efficiency with no detriment to clinical and quality of life outcomes.199 
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Further work is required to ascertain the most appropriate role for primary care. Secondary 
care based, nurse-led clinics using remote follow-up (e.g. telephone, internet, postal) or 
outreach clinics based in the community provide alternative models requiring less input from 
primary care. 
Conclusion 
Our understanding of the key elements of good survivorship care is growing.  As the numbers 
of cancer survivors continue to increase and at least some cancers become more akin to other 
chronic conditions, primary care has a potentially important and increasing role to play.   
 
Action points 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New models of cancer follow-up care are required  that draw on 
the principles that apply for other long term conditions  
Following further development to arrive at the optimal model, 
survivorship care plans should become a feature of follow-up care   
The role of PCPs in survivorship care needs to be more clearly 
defined.   
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Part 6: Palliative care in Advanced Cancer 
 
A third of patients diagnosed with cancer will die from their disease.200 The conceptual approach to 
the transition from curative to palliative treatment intent has changed from being a point in time to 
being a gradual introduction of the idea of hoping for the best but preparing for the worst. As the 
chance of cure diminishes, there is less of a role for oncology treatments and more involvement of 
palliative care.  Patients frequently want to spend most of their time at home and most express a 
preference to die there.201  While this requires a significant role for primary care, this transition may 
be from specialist team to specialist team, with little thought of engaging the primary care doctor in 
a meaningful way.202 
 
Although ideally all PCPs would be involved in palliative care, the rate of their involvement in 
palliative care in developed countries ranges from around 85%203, 204 to less than 50%.205 There may 
also be differences in PCP involvement between urban and rural settings.202  
 
Palliative care  and primary care practice  both take the perspective of treating the whole person, 
their immediate family, the application of best practice and consideration of issues beyond the 
physical to encompass psychosocial, practical and spiritual issues. The difference is that palliative 
care is more intense and shorter timeframe, compared with broader primary care. The nature of 
the care is the same.   
 
We examine the evidence for and against primary care involvement, the barriers and facilitators 
that exist, and describe the level of primary care involvement that health systems should aspire to. 
 
The value of primary care in end of life care 
Primary care is in a unique position to provide palliative care. It has the ability to start early in the 
course of the life-threatening disease, meet all dimensions of need (physical, social, psychological, 
spiritual), provide care in clinics, care homes and at home thus preventing unnecessary hospital 
admissions, and support family carers and provide bereavement care.206 Having a regular PCP, 
particularly one who does home visits, increases the chance of dying at home207 and reduces 
emergency department visits.208  
Done well, primary palliative care is valued by patients and carers.209 Accessibility is an important 
element of their satisfaction209, as is symptom control.210 However, there is considerable room for 
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improvement,210, 211 with lack of confidence and unwillingness to assume responsibility for palliative 
care being major factors.204  
 
Primary care and national health models  
The provision of palliative care by PCPs is highly dependent on the policy environment in which 
they operate.  Factors include the place of the PCP in the healthcare system, access to essential 
medicines, the existence or otherwise of community nurses attached to primary care, and health 
insurance arrangements.212   
 
The WHO Public Health Strategy for palliative care describes four domains of public policy to 
facilitate community based palliative care.213 (Figure 6.1) Primary care involvement in palliative care 
should be embedded in all of these domains. 
 
  
Figure 6.1: The WHO policy for successful integrated palliative care      
 
Governmental health policies will in future be judged by the WHO in part on the basis of their 
delivery of palliative care.214 Because most deaths will not involve specialist palliative care 
practitioners, facilitating primary care practitioners to deliver timely, competent end of life care has 
to be a core part of national palliative care strategies.  The European Association of Palliative Care 
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(EAPC) has adapted the WHO policy framework to identify the place of primary care in end of life 
care at a national level.212 
 
National policy settings that facilitate this in primary care are not always in place. Of 20 European 
countries reported in an EAPC sponsored review212, only two keep palliative care registers in 
primary care, eight are encouraged to use tools to identify patients at risk of dying in the 
foreseeable future, and half have community nurses that work with primary care. Home visits are 
available in all but three countries. Payment structures for PCPs can make end of life care more or 
less attractive, while specialist support ranges from extensive to limited.  
  
Availability of appropriate medicines  
In order to deliver palliative care in the community, PCPs must have access to appropriate 
medicines and education in their use. Both the World Health Organization (WHO) and IAHPC have 
published lists of recommended medicine lists for palliative care.215, 216 Symptom management 
guidelines have also been developed within specific countries, and reflect the national and local 
availability of particular medicines. 
 
Barriers to primary palliative care 
The barriers that prevent PCPs from being involved in palliative care can be grouped broadly into 
logistical or practical barriers; barriers related to coordination of care; barriers related to perceived 
competence in palliative care; and personal barriers. However, these barriers overlap and are not 
mutually exclusive.  
 
Logistical issues related to time and traveling to provide home visits are cited by PCPs as prominent 
barriers203, particularly outside of regular office hours. Providing palliative care is time-intensive, 
because of the complexity of symptom management, the psychosocial issues that arise or are 
intensified at the end of life, the necessity of communicating sensitively with both patients and 
their families, and the fact that care is often delivered in the home setting.204, 217  
 
Willingness to provide care after hours varies widely by country. In part it depends on remuneration 
and availability of large-scale out-of-hours cooperatives.218 Out-of-hours availability correlates 
positively with PCPs’ perceived duties of care, and negatively with being in a salaried job, working in 
a city-based practice, and living far from the practice.219  
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Issues related to organization of care are prominent if potentially modifiable barriers to palliative 
care provision by PCPs. Patients may lose contact with their PCP after they are diagnosed with 
cancer.220 It then becomes difficult for the PCP to become re-involved at the end of life in the care 
of a patient with whom they have had little contact. This issue may be compounded by poor 
communication between specialists and PCPs.221  
 
Both oncologists and PCPs may have difficulties recognizing patients who are in need of palliative 
care, resulting in delayed referrals and poor planning.222 Prognostic estimates are notoriously 
optimistic223 and this may delay the commencement of a palliative approach and increased support, 
particularly in countries such as the United States where hospice services are linked to a prognosis 
of less than 6 months.224  
 
Once PCPs are involved in palliative care, there may be other barriers on an organizational level. 
Dutch PCPs reported that it was time-consuming to arrange home care services or procedures such 
as oxygen, intravenous medications, or paracentesis, and difficult to obtain extra care.217 Those in 
rural areas may have less access to education programs and advice from specialists.225 Lastly, they 
may feel that palliative care is not sufficiently valued or remunerated:206  extra fees are available for 
palliative care home visits in the Netherlands, Norway and Denmark but not in the UK; in 
Luxembourg patients must pay directly for home visits.212  
 
Lack of expertise in providing palliative care is another prominent barrier.226 One systematic review 
reported that PCPs often did not feel fully competent to deliver palliative care, particularly in 
relation to control of symptoms other than pain, emotional distress of patients and relatives, and 
bereavement care.227  Subsequent surveys have confirmed that these inadequacies persist although 
interest in education in palliative care is strong. Lastly, they may not involve themselves in palliative 
care because they have little or no interest in doing so, or because of personal or family 
commitments.204  
 
Enablers for PCP provision of palliative care 
The success of some countries in addressing the barriers described above can be attributed largely 
to structured programs, services and educational opportunities to support PCPs in the provision of 
palliative care.  
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In a survey of PCPs in the UK, agreement that palliative care was a central part of their role 
increased with the number of physicians in the group, from 47% for solo physicians to 85% for 
groups with >8 physicians.203 In some countries such as Netherlands, Denmark and the UK, the 
establishment of out-of-hours cooperatives has changed the manner in which care is provided.  
 
One challenge for these services is the transfer of information regarding terminally ill patients from 
the primary PCP to the out-of-hours service. When such transfer does occur, it is associated with 
positive outcomes including fewer hospital admissions.228  In Scotland and in many parts of England 
an electronic Palliative Care Summary is available to provide out-of-hours staff with an up-to-date 
briefing of patients’ medical history, understanding and wishes.229 Access by the covering physician 
to patients’ electronic records promotes continuity of care, and provides medical information for 
patients whose decline was not anticipated.  
 
Collaborative care is important not only among GPs, but also between GPs and other health care 
providers, including oncologists, community nurses, and palliative care specialist teams. Patients 
value ongoing care by their GP but are at times unsure of their GP’s role following a cancer 
diagnosis.230  Oncologists can promote continued involvement of GPs throughout the cancer 
trajectory by regular communication about their mutual patients and by encouraging patients to 
continue to maintain contact with their GP.230  Interdisciplinary teamwork can facilitate the 
organisation of care; for example the job of coordinating palliative care, may be delegated to 
community nurses, with the GP acting as a point of contact for problems.231  
 
Specialist palliative care teams improve quality of life, mood, satisfaction with care and possibly 
even survival when involved early in the care of patients with advanced cancer,232 enable patients 
to die in the setting of their choice233  and play an important role in supporting PCPs. PCPs may 
work with these services in different ways, using them as a resource, working together as an 
extended team, or handing over responsibility completely. Clear allocation of responsibilities is 
important, whichever model is adopted.234  
 
In addition to support from palliative care teams, education of PCPs is essential to increase their 
confidence in providing palliative care. This includes improved palliative care education during 
medical training, continuing education through workshops, online courses and training programs, 
and access to resources such as care pathways and websites.  In countries such as Japan, courses 
have been developed to provide primary palliative care education in primary care.235  Electronic 
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resources such as Caresearch in Australia provide access to comprehensive educational and 
research material.236  
 
In the UK, initiatives like the Liverpool Care Pathway (LCP) and Gold Standards Framework have 
been developed to improve end-of-life care in generalist settings.237, 238 The importance of applying 
the principles of end of life care planning properly, using them as a guide to high quality care and 
not simply a task to be signed off, has been demonstrated by the criticism that application of the 
LCP has received, and the recommendation to refer to end of life planning rather than a clinical 
pathway.239 
 
Specific tools and interventions have also been designed to promote early identification of patients 
with palliative care needs. Simple prognostic tools have been developed based on performance 
status and other clinical indicators. Routine use of the “surprise question” (“Would you be surprised 
if this patient died within a year?”) was effective in predicting one-year survival of patients with 
advanced cancer.240 In Ontario, Canada, symptom screening together with symptom management 
guidelines has been incorporated into all cancer centres241 and is now being incorporated into the 
practices of PCPs. A range of tools to identify patients in primary care at risk of dying from cancer 
and other causes have been developed or are in various stages of testing.242  They all use a 
combination of subjective clinical judgement, non-specific indicators of deterioration, and disease 
specific markers of deterioration to highlight people at risk of dying. 
 
There is also increasing acknowledgement that palliative care is emotionally taxing for those 
providing it and that self-care of PCPs is essential to mitigate compassion fatigue and burnout.243  
Specific interventions that increase self-awareness, as well as informal self-awareness practices, 
may enable physicians to continue providing palliative care with empathy and effectiveness.  
 
Facilitating primary care into multidisciplinary care  
Appropriate end of life cancer care should be needs-based with the level of services matching the 
complexity of need.  For most of the cancer journey, the problems the patient will face are 
relatively straightforward and well within the competency of the PCP. Specialist involvement could 
range from a telephone consultation to a single visit, to full care.  The system should be designed to 
facilitate seamless transitions to the most appropriate level of care.  Taking this approach and 
evaluating patient needs regularly, using a needs assessment tool, optimizes the use of scarce 
resources, and reduces the intensity of patient and carer needs.244  
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Much of palliative care is complex. It requires coordination of health professionals and appropriate 
resources.  The elements of good integrated planning include:  adequate resourcing of all 
professionals, appropriate knowledge and skills, good communication between professionals and 
active engagement with the patient and carer, the health system clarity, and effective management 
systems and decision making capacity.245  
 
The fragmented nature of some health care systems can make the engagement of primary care in 
the management of advanced cancer patients an operational challenge. However, the outcomes 
may be worth the effort. For example, two RCTs have shown a single case conference involving a 
PCP and specialist palliative care team confers benefits, including improved patient performance 
capacity, less hospital and ED referrals246, and improved quality of the patient’s life in the last 
month of life.247  
 
PCPs also have a role in caring for the carers of persons with advanced cancer. The use of a self-
completed questionnaire to facilitate a carer-focused consultation reduced intensity of needs in 
carers who were anxious or depressed. Those caring for very ill people articulated more needs, 
which potentially allowed them to be addressed.248  
 
 
Advance care planning 
Advance care planning is a process that allows people to express their choices about their future 
care in a document that is legally binding should they become incapable of expressing them due to 
advancing illness.  Most developed countries have enacted legislation to facilitate this. Advance 
care plans are effective in ensuring that the patients’ wishes are known and followed, reducing 
futile and unwanted treatments in hospitals and leading to more satisfied bereaved carers, who 
experience less anxiety and depression.249 The process may also facilitate a more timely, smooth 
transition to end of life care.  
Advance care planning should also address clinical care that anticipates and prepares for potential 
clinical problems. Generating a case management plan that takes in to account the patient’s goals 
of care and treatment wishes can ensure that they are enacted. The absence of this sort of 
approach may lead to a more reactive, crisis driven form of care. (Figure 6.2) 
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Figure 6.2 Conceptual map of advance care planning 
 
Ideal primary palliative care for advanced cancer 
A person with advanced cancer who approaches the end of life would ideally have this 
recognized early by the oncology team. Supportive and palliative care would be presented 
as a means of hoping for the best but preparing for the worst.  Because the PCP has been 
part of the team, and has had a role in assessing and managing the carer’s needs as the 
disease progressed, his or her involvement would be a matter of course.  The PCP would 
work with the specialist palliative care team to develop a care plan that respected the 
patients’ wishes, and ensured that each team members’ responsibility were clearly set out. 
A copy of the patient’s advance health directive would be in the clinical notes and readily 
available to all relevant health professionals.  
 
In the community, the PCP would commit to regular review of the person, performing home 
visits where necessary. He or she would have had effective training at undergraduate and 
vocational training levels and would have been treating palliative patients from the 
beginning of their professional career, receiving subsequent case based training through 
shared care of multiple patients over time. The PCP would have ready access to, and use 
regularly, evidence based treatment guidelines. The care provided would extend to the 
bereavement phase of the carer. Lastly, the health system would recognize the complex 
nature of this care, and provide appropriate remuneration for the extra effort involved.  
60 
 
Action points 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Palliative care services should be integrated and be based 
on the WHO Public Health Strategy for palliative care 
 PCPs should participate in provision of palliative care. 
They should be supported, provided with high quality 
training and adequately resourced to do this. 
 All patients receiving palliative care should have an 
advance care plan, which should include a plan for their 
clinical care 
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Part 7: Integration between Primary Care and Cancer Specialist Care 
 
Integration of services between primary care and cancer specialist care is vital to optimize the 
quality and outcomes of care,250 and yet is known to be problematic.251  Patients often need to 
consult many health professionals across multiple healthcare settings. This can lead to 
fragmented and uncoordinated care190, 251 which, in turn, can jeopardize quality and patient 
safety.252  Accordingly, introduction of models and tools to improve integration is essential to 
optimize the role of primary care along the breadth of the cancer care continuum.  We review 
here approaches to models of care, how these can be applied to the structuring of healthcare 
services, and tools that have the potential to facilitate integration between primary care and 
cancer specialist care. 
 
Part 7 Panel: Integrated Care: Elements and Tools 
Elements of Integrated Care: 
Clinical Integration:  
 Establishing processes to coordinate patient care 
 Clear definition of clinical roles, including interdisciplinary health professionals 
Vertical Integration: 
 Establishing structures and processes to support coordination between the formal 
cancer system and community-based primary care 
Functional Integration: 
 Establishing structures and processes to enhance coordination between provides in 
health and non-health settings 
Tools to Facilitate Integrated Care: 
 Care paths 
 Education and audit 
 Patient Navigation 
 Electronic Communication Tools 
 
 
Models of Integrated Care  
The concept of care integration is pervasive in the medical literature, especially when 
considering the care of cancer patients with complex medical and psychosocial needs that is 
delivered by a variety of providers with distinct roles and skills.  Integration between 
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providers is defined as the process of creating and maintaining a common structure and 
connection between different providers for the purpose of coordinating patient care, while 
retaining each provider’s unique role.253  Integration can be seen to have 3 core elements254 
that need to be considered in the design of models of care (Table 7.1).  
 
Clinical integration: the extent to which patient care services are coordinated across the 
various functions, activities and operations units/levels of the cancer system. These would 
involve structures and processes to define and clarify clinical roles and can include education 
and training of interdisciplinary health professionals such as patient navigators or clinical 
nurse specialists. 
Vertical integration: structures and processes to support regional collaboration, 
coordination and leadership with respect to the delivery of cancer services both in the 
formal cancer “system” as well as in community settings that involve cancer and non-cancer 
providers. Examples would include care pathways and guidelines for care.   
Functional integration: structures and processes to support key coordination activities 
across providers such as platforms to enhance communications such as electronic tools. 
These structures and processes can also enhance connections between providers in health 
and non-health (e.g., social care) settings, fostering horizontal integration especially at the 
level of the community. 
Table 7.1 Elements of integrated care 
 
These elements of integration are brought together operationally in the way in which health 
services are structured through the design of  models of care,255 which represent a 
systematic approach to achieving high quality, holistic care that address all the needs of 
patients living with cancer.   
 
The components of a model of care include the settings (cancer centre, hospital or 
community) and providers (oncologists, nurses, family physicians) involved with operational 
specifics (care pathways, care plans, information systems) informed by the elements of 
integration.  There is fairly well established evidence to support the transition of well 
patients with certain cancers during survivorship to primary care settings.256  This body of 
research demonstrates equivalent cancer outcomes, better overall care (through 
management of non-cancer health issues) better supportive care and lower cost.257  For 
many cancer patients with ongoing complex needs during and after cancer treatment, a 
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shared care approach is proposed,258 but the operational specifics are more involved and 
published evidence on how to achieve this even in settings where primary care is well 
established, are limited. In the subsequent sections we review how healthcare services can 
be structured to enable integration at various stages of the cancer care continuum; and 
propose tools that can be used to facilitate integration.  
 
Structuring of Healthcare Services 
The possibilities for integration depend on the actual organisation of the healthcare system 
and are very different for high-income and low-income countries, as well as for the different 
stages of the cancer continuum.  While much of the available research reflects efforts to 
transfer, substitute or relocate from specialised treatment to primary care, there are very 
few examples of real integration. 
 
In most countries, primary care is responsible for primary prevention and major effects of 
primary prevention of cancer are based on public health policy initiatives by legislation (e.g. 
smoking and taxes) together with environmental and occupational initiatives.  In low and 
middle income countries, where prevention might be the most effective approach to cancer 
control  WHO has proposed a model for integrating primary prevention with screening 
(secondary prevention of asymptomatic disease)259 so that primary care forms a clinically 
integrated system linking  the two.  
 
In many countries although screening programmes are centralized and managed by health 
authorities, they are usually integrated between primary and secondary healthcare 
(although there are substantial difference among systems).  The main efforts of such 
programmes relate to maximising uptake, improving access, and providing efficient 
screening. In high-income healthcare systems it seems that integration between primary and 
secondary care increases these measures of screening effectiveness.260 
 
Cancer diagnosis relies on an accessible healthcare system and access to relevant 
investigations; thus well-established integration between primary and specialist care is 
critical. There is an ecological association between health care systems where primary care 
functions as a gatekeeper and poorer cancer outcomes.44 It has been suggested that this is 
not due to the gatekeeper function per se, but rather to the lack of integration with respect 
to PCP access to cancer investigations (e.g. imaging and endoscopies). This concurs with 
64 
 
studies showing better cancer control where there is better access to both primary care and 
specialised care.261, 262    Research has shown that integrating cancer investigations is possible 
and might have positive effects.263, 264 In a number of healthcare systems urgent referrals 
pathways for suspected cancer have been implemented as a means to integrate primary 
care and specialist care.16, 265  
 
Very little research has been done on integration during cancer treatment257 and has mainly 
been focused on information and communication skills. There are, however, important 
reasons for better integration of primary care and specialist care during active cancer 
treatment: symptom control266 and management of toxicities to avoid emergency 
department visits and hospitalizations;267 management of patients with concurrent mental 
health problems;268 and management of geriatric patients with multimorbidity.269 
 
Follow-up, after-care and survivorship after cancer diagnosis has traditionally been based on 
specialist care. However, acknowledgement of increasing cancer incidence and concerns 
about efficiency have fostered calls for studies on integrating follow-up care after cancer.270   
Randomised trials evaluating primary care led follow-up of cancer survivors in the UK196, 
Canada197 and Australia198, 271 show that integrating follow-up produces improves patient 
satisfaction with no negative consequences on cancer outcomes and better cost-
efficiency.196, 197 
  
Palliation is an area with a long tradition for integration of primary and specialised palliative 
services, largely predicated on models of shared care and collaborative care and is 
addressed more fully in section 6.  
 
Tools for Better Integration 
Care paths 
Care pathways for patients with cancer have evolved as a result of marked variation in 
treatment and outcomes for patients in an attempt to equate outcomes both within and 
between countries.  Such patients can present via screening programmes as for breast, 
prostate and colorectal cancer or via primary care, whether presenting with or without 
“alarm symptoms”, or as an emergency with for example bleeding or perforation. It is crucial 
that regardless of route of presentation, care pathways are coordinated so that there is no 
delay in investigation and diagnosis, accepting that the vast majority will not have cancer.  
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In the developed world the management of cancer is now multimodal usually involving a 
combination of surgery, radiotherapy, chemotherapy and hormonal manipulation.  This 
requires management by a multidisciplinary team.  Such teams are usually led by a surgeon 
or oncologist assisted by a pathway manager, a role usually filled by a nurse specialist or 
administrator who provides a direct point of contact for the patient and carers, and ensures 
full distribution of decisions of the multidisciplinary team.272 
 
As care becomes more complex, communication between patient, carers, primary care 
physicians and the clinical team is vital and this is best managed through frequent 
multidisciplinary meetings273 and joint specialist clinics with same day communication with 
primary care.  The care pathway must be flexible for the individual and not driven primarily 
by prescribed targets. Such pathways have led to centralization of services which for certain 
cancers (e.g., oesophagogastric) has improved the surgical outcome.274  It is important 
however to ensure that as much of the pathway (diagnosis, staging) as possible is delivered 
close to home, restricting travel to what is necessary for essential oncology and surgery. 
 
 
In conclusion, care pathways for cancer are complex and multifaceted. There is good 
evidence that they have standardized outcomes for high-risk cancer within and between 
countries25, 47 They start with presentation and involve all specialties with the patient and 
carers at the centre.  Quality of life is central to all decisions and the pathway should be 
adapted to take account of advances in treatment and patients encouraged to be enrolled in 
trials wherever possible. 
 
Education and Audit 
Education is arguably the cornerstone of integration of cancer care across sectors.  
Education must flow both ways, be tailored to full range of primary care and specialist 
health professionals involved with cancer care, and inform the changes needed to achieve 
highest quality care. This will be an enormous, costly and time consuming agenda, 
particularly because evidence is lacking as to the optimal modes of education to improve 
integration of primary care and oncology.   
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Integrated oncology education is less well developed than programmes for other disease 
areas such as heart disease or diabetes.  Lessons from those areas are abundant, but it is still 
uncertain whether education is best delivered in a multidisciplinary format.275  Given the 
breadth of the cancer control continuum,9 relevant education for health care professionals 
will vary along the continuum, by tumour type, age of the patients, and multimorbidity.  This 
must be complemented by education about communication systems, referral and re-referral 
processes, team coordination, and processes of care.  Integration will ideally lead to a 
patient experience of ‘seamless’ care, informed by both their needs and high quality, 
equitable provision.  Cross sector education about key differences in the prevalence and 
presentation of disease in each setting will help health practitioners appreciate each other’s 
roles, and grasp diagnostic and investigation problems.  Frameworks that underpin 
measurement of cancer related processes, for example the Aarhus Statement,5 or ongoing 
management of cancer care276 and statements promoting shared care models277 should 
inform international curriculum development.  
 
There is little research regarding the most effective type of educational interventions for 
enhancing integration of cancer care.  Outcomes should include improvement of systems, 
better communication, improved knowledge and diagnostic expertise, and increase in 
relevant competencies across sectors.  Agreed curricula across and between primary and 
specialist care are needed.  One relevant systematic review from the US, regarding skin 
cancer education for primary care physicians showed promising effects from a range of 
isolated educational interventions but noted the need for improved methodological 
rigour.278  
 
Cross national audit is a powerful tool for illuminating variations in care that could be 
addressed with specific interventions at the primary care / specialist interface.  The 
International Cancer Benchmarking Partnership, considered in more detail in Part 8, has 
illustrated large national variations between national guidelines and patterns of cancer care, 
and highlights what countries can learn from each other.279  
 
Effective audit and education needs to extend beyond clinical content to the nature of care 
pathways, quality and governance mechanisms, and quality enhancing practices such as 
access to clinical trials.  A key driver for improving integration across sectors will be unified 
electronic information systems across sectors; good education and training in the use of 
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such systems across sectors will allow for harmonization of care, enable regular clinical audit 
and provide a platform for feedback systems to record and analyse errors and near misses.  
A systematic review of audit and feedback interventions for health professionals in other 
cross sector clinical areas suggests they tend to make small but important improvements in 
clinical practice.280  
 
Finally it will be important to harness educational capacity from health care providers, the 
higher education sector, and third sector sources.  Some clinicians already working at the 
primary / specialist interface, such as nurse specialists, may have key roles as both educators 
and change agents. 
 
Patient Navigation 
Patient navigation is one model of interdisciplinary care with the expressed goal of 
improving integration.  Patient navigation has its origins in 1990 with an initial 
demonstration project in Harlem, NYC to address disparities in access to cancer services for 
vulnerable populations.281 The principle of navigation is to provide active coordination of 
care that removes barriers to access.  Navigation programs seek to provide patients and 
their families with a map and a guide (the navigator) to overcome system fragmentation.  
This is of particular interest when a number of providers are needed to manage both cancer 
and non-cancer health issues.  Most studies of navigation in cancer have involved nursing in 
this role.  A recent randomized trial of use of a navigator early in the care trajectory of newly 
diagnosed breast, colorectal and lung cancer282 demonstrated clear improvements in the 
patient experience over usual care, and greater adherence to therapy, although no 
differences were seen in quality of life.  The role of a navigator may be of particular interest 
during active therapy.  A navigation program that  coordinates care between primary care 
providers and oncologists in vulnerable populations such as the elderly, patients with pre-
existing significant co morbidities and those undergoing complex therapies with significant 
toxicity (for example head and neck cancer patients) could overcome gaps in the 
management  of comorbid conditions that result in suboptimal outcomes.  Given the 
positive results on patient reported outcomes, further studies using navigators with a 
specific focus on provider integration in at risk populations are warranted.  
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Electronic Communication Tools 
With the rapid growth of eHealth technology and the computerization of clinical practice, 
electronic tools are being widely implemented in the care of patients across the cancer care 
continuum; computer-based risk assessment tools are being employed for screening, 
decision-support systems are being used at points of diagnosis and treatment, and secure 
patient portals facilitate remote or self-management of symptoms and side-effects.283, 284 
Electronic communication between patients and physicians could bring about care that is 
individualized and make information readily accessible across settings.285  In primary care, 
patients and health care providers alike have expressed comfort with the notion of using 
electronic communication, such as email, as a means of facilitating care processes286 and 
there is evidence to suggest that electronic patient-physician communication can lead to 
improved clinical and patient-reported outcomes.287 There is relatively little research 
available on electronic communication tools in the cancer context but there is ample scope 
for such tools to be used to connect primary care physicians and cancer specialists to 
improve continuity of care.287 
 
Conclusion 
Better integration between primary care and cancer specialist care throughout the cancer 
care continuum is vital to improve the quality of care.  We have summarized a range of 
strategies that have the potential to facilitate better integration: the way in which 
healthcare services are structured, care paths, education and audit, care navigation, and 
electronic communication tools. However, to date, the extent to which any of these 
strategies have been evaluated and implemented is limited.  Rigorous evaluation through 
pragmatic randomized trials and assessment of how differing contextual factors might 
impede or enhance effectiveness is warranted. 
 
 
 
 
 
 
 
 
 
69 
 
Action points 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Care pathways are key to integrated care but effective lines of communication are 
vital for their success 
 Cross-sectoral education is central to integrated care and should extend beyond 
clinical content to include care pathways, systems and quality improvement. 
 Patient navigators show promise as a means of enhancing integrated care and 
should be further evaluated 
 Healthcare providers and policy makers must adapt evidence-based models and 
tools to improve integration between primary care and cancer specialist care for 
each phase of cancer control .  
 These must be introduced with strategies for implementation, adoption, and 
sustainability that are of proven effectiveness. 
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Part 8:  Health Policy on Primary Care and Cancer Control  
 
While the incidence of cancer is increasing, partly as a result of a rapidly growing aging 
population, the number of cancer survivors is also increasing due to improvements in 
diagnosis and treatment.   However, these gains are not experienced in every health system 
or in every social group with some countries performing much better than others and some 
population groups experiencing better care and outcomes. The reasons for this variation are 
complex and for the most part remain poorly understood. 
 
This somewhat mixed picture has significant implications for primary care both in terms of 
early diagnosis and after-care.  Family physicians will treat more cancer survivors in future 
years since we know that cancer survivors visit their PCP more often than non-cancer 
controls.164   A recent report from the Institute of Medicine concludes that the needs of 
cancer survivors are not being adequately addressed.190 These needs centre on psychosocial 
support, treating the long-term complications of cancer treatment, addressing on-going 
symptoms, recurrences and new cancers, and accessing information about the disease. They 
are all tasks that PCPs are well-placed to perform. 
 
Starfield has shown that investing in primary healthcare is the foundation of any high 
performing health system.27   Countries with stronger primary care generally have healthier 
populations and a more equitable distribution of health in populations, a finding that holds 
in studies across and within countries.  Such a development is also supported by other 
policies aimed at universal health coverage promoted by the WHO and World Bank.  In many 
countries, there is growing emphasis on models of integrated care which bring together 
primary, secondary and social care.  Integrated care lies at the heart of moves towards 
universal health coverage.  These moves are partly driven by cost control imperatives to 
ease demand and pressure on expensive secondary care services, despite the lack of 
evidence for such a conclusion, but also because they are seen to improve patient outcomes.       
This section is structured around three key areas affecting the performance of primary care 
in cancer control: lessons for policy-making from international comparisons; primary care, 
cancer and gatekeeping; and financial incentives to improve the quality of cancer care.   
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International comparisons 
International studies comparing cancer outcomes have focused policy makers’ attention on 
cancer diagnosis, treatment and survival outcomes. The EUROCARE (EUROpean CAncer 
Registry), collaboration has produced comparative evidence about the survival of cancer 
patients in different European countries since 1995.288, 289  Despite initial scepticism about 
data comparability by some authors, EUROCARE has transformed public policy on cancer 
control in many European countries. In the UK, the publication of data from the EUROCARE-
2 study in 1999 underpinned the launch of the first NHS Cancer Plan in 2000.290 UK policy 
responses initially focused on improving the effectiveness of treatment services; however, 
attention has more recently shifted to timeliness of presentation and diagnosis.291  A similar 
policy direction has been pursued in Denmark where poor cancer survival rates led to the 
production of three national cancer plans accompanied by significant additional funding.  
Comparisons with the other Nordic countries through the NORDCAN collaboration led to 
increased political awareness.  While policy initiatives have focused on cancer treatment 
outside primary care, in recent years there has been a growing awareness of the important 
role of primary care in improving outcomes.      
 
Panel 
Key policy areas affecting the performance of primary care in cancer 
control 
 Lessons from international comparisons: there is variation in public 
awareness, attitudes and beliefs about cancer. There are also 
differences in health care systems but the role of organisational factors 
is inconclusive 
 Financial incentives: Financial incentives to doctors or to patients may 
improve the uptake of screening tests for cancer but there is no 
evidence that they would improve other aspects of cancer care. 
 Gatekeeping: there is little research on its impact on quality of care, but 
it may lead to rationing of PCPs’ use of investigations.   
 Improvements to the gatekeeping role and cancer diagnostic pathway 
may achieve greater gains than incentivisation 
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Two important observations can be drawn from the current landscape of international 
comparative studies of cancer outcomes. First, with few notable exceptions including the 
two CONCORD studies,292, 293  most of the research is concentrated in a small number of 
countries with a relatively high index of human development. Secondly, again with few 
notable exceptions, the vast majority of available evidence relates to a single (albeit 
important) outcome measure, namely cancer survival.  There is a distinct paucity of 
comparative evidence about the population and healthcare system determinants of survival, 
including public understanding of cancer symptoms, timeliness of diagnosis, availability, 
quality and uptake of screening programmes, and quality of cancer treatments – including 
that of patients with advanced disease. 
 
Knowledge concerning the reasons for variations in cancer outcomes is difficult to acquire 
but evidence about variation in determinants of survival is required to support cancer 
control policies.   Increased attention to the diagnostic pathway and role of primary care has 
led to the formation of the International Cancer Benchmarking Partnership (ICBP) project, 
involving 12 jurisdictions in 6 countries (Australia, Canada, Denmark, Norway, Sweden and 
the UK).279 ICBP is a comparative multi-modular study that aims to both deepen and 
complement epidemiological evidence with studies of variation in psychosocial or healthcare 
factors. ICBP evidence thus far has confirmed variation in survival between jurisdictions.294  
Furthermore, ICBP studies indicate that psychosocial factors, such as awareness of 
symptoms and attitudes and beliefs about cancer among the public vary between 
jurisdictions but are not associated with survival in a straightforward way. Fig 8.1) Still, such 
differences might be important as there is also variation in how healthcare systems are 
organised around the cancer diagnosis.  Nevertheless, evidence about the role of 
organisational factors (including, for example, the way primary care is organised, the way 
new treatments, including pharmaceutical and interventional treatments are introduced in 
clinical practice after health technology assessment, and the role of private medical practice 
or insurance coverage) is inconclusive.40  
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Fig 8.1 Inter-country differences in awareness of cancer risk 
295
 
 
Primary care, cancer and gatekeeping  
A key feature of strong primary care systems is the gatekeeping role, acting as the first line 
of the health care system.296 Gatekeeping can be combined with a patient list for which the 
GP is responsible and in varying degrees people are required to access services via contact 
with primary care in the first instance.  
 
Gatekeeper systems can be in the interest of policymakers for reasons of resource 
management. While people should have access to the health care they need, at the same 
time health care has to be affordable.  Encouraging patients to seek support from general 
practice in the first instance conserves hospital resources and is therefore seen as desirable 
and more cost-effective. Consequently, some health care systems provide health care 
enrolment at reduced cost if people choose to have a gatekeeper and register on a list.297  In 
many gatekeeper systems, 90-95% of all patient contacts are managed solely in primary 
care.298  Arguments against gatekeeper systems centre on the patient’s lack of freedom of 
choice to obtain a second opinion, and on the detrimental effect on patient-doctor trust that 
might arise from the doctor's prerogative to decide on any referral to secondary care.299 
A gatekeeper system has an important impact on the role of primary care in preventive work 
and health promotion, in diagnostic work, in the treatment of minor illnesses, in visits to 
specialised treatment, rehabilitation and follow-up.  Despite its significance as a mainstay of 
effective primary care, remarkably little research has been conducted on the possible impact 
of gatekeeping on the quality of care.  
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Prevention, screening and health promotion 
Primary care has been successful in delivering evidence-based screening tests, e.g.cervical 
cytology, and HPV immunisation. Health care systems with a gatekeeper function are 
associated with higher utilization of recommended cancer screening procedures compared 
to those without.300  
 
Diagnostic work up 
Although there has been a tendency to blame GPs for poor and slow diagnosis, causes of 
delays are much more complex and multifactorial, and inadequate clinical competence is an 
unlikely cause.10 Access to diagnostics and specialist assessment for suspected cancer is a key 
consideration in health care systems with gatekeeping, and has been blamed for diagnostic 
delay.   
 
Cancer presents in the early phases with a spectrum of symptoms.9   Good access to primary 
care may be a factor in providing better diagnosis of cancer, though the evidence for reform 
of access to specialist assessment reducing time to diagnosis is stronger.301 In contrast to this 
view is evidence of a correlation between lower cancer survival and the strength of the 
gatekeeper system – although other country-level factors (such as service organisation) may 
also be involved.44 This suggests that in some health care systems the gatekeeper is rationing 
the use of investigations by setting a higher threshold for referral. Further, the pivotal 
interaction between patient and GP can be adversely affected if the GP is reluctant to refer, 
with patients coming to believe that symptoms have to be serious before visiting their GP.   
 
Progress can be made by policies that aim to accelerate and integrate the diagnostic 
process. Recently, political awareness of this initial step in the diagnosis of cancer has led to 
the National Awareness and Early Diagnosis Initiative in the UK, the Danish’ three-legged 
strategy’ for cancer diagnosis (Fig 8.2) (urgent referral for those with alarm symptoms, 
diagnostic centres for those with non-specific but serious symptoms, ‘No-Yes clinics for 
other patients in whom the PCP needs rapid access to simple investigations in order rule 
cancer out (No) or in (Yes)) and most recently the ACE (Accelerate, Co-ordinate, Evaluate) 
initiative in the UK. 302-303 In Denmark, the diagnostic interval has shortened significantly and 
direct access to investigations has been appropriately utilised.301, 305 Progress can also be 
made by technological innovation in point of care testing and detailed clinical audit studies. 
It is, however, important to realise that any system that makes referral contingent on the 
75 
 
presence of symptoms with a high positive predictive value risks delays in the diagnosis of 
those with less specific symptoms.  
 
  
 
Figure 8.2  The structure of the Danish three-legged diagnostic strategy303 
 
Follow-up and survivorship  
The gatekeeper role in follow-up, survivorship and end of life care is addressed in an earlier 
section of this Commission.  
 
Performance measurement, public reporting and financial incentivisation to improve the 
quality of cancer care 
Routine measurement of cancer burden and related diagnostic activity in primary care can 
help to underpin public reporting and financial incentivisation of care quality. In England, 
indicators relating to the burden of cancer, diagnostic and screening activity for each 
individual general practice has been collated since 2010 and reported publicly since 2013.306   
Summary statistics by practice are made available to practitioners and managers, to 
motivate reflective learning, and in recent years they are reported publicly. However, 
evaluations of the effectiveness of these quality improvement initiatives are lacking. 
 
As is the case for any quality improvement policy, indicators need to reflect processes of 
care that are clearly amenable to improvement. In England, public reporting of the 
frequency of 3 or more pre-referral consultations among patients subsequently diagnosed 
with cancer has been proposed. However, such events often result from factors other than 
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the quality of clinical reasoning of individual doctors, for example the need for primary care 
investigations prior to referral.307  
 
The UK was the first country to experiment with financial incentives for cancer care with the 
introduction of incentives to reach cervical cytology targets in the early 1990s. At that time 
few primary care practices had computerised medical records and the introduction of the 
incentive was associated with the rapid development of recall systems, and an increase in 
the percentage of practices meeting the target of 80% of eligible women screened from 61% 
in 1991 to 88% in 1999. Furthermore there was a reduction in inequalities in the delivery of 
care over that period.308 
 
In the United States, incentives to primary care clinicians to promote cancer screening are 
now common though not universal.  Screening for breast, cervical, and colon cancer are 
HEDIS measures established by the National Committee for Quality Assurance to evaluate 
health plans309 and to achieve high HEDIS scores, plans often provide incentives to primary 
care clinicians to promote screening, although monetary amounts vary considerably.   
Cancer screening as a measure of high quality care is also included in most emerging 
Accountable Care Organization (ACO) payment models.  Although the distribution of surplus 
dollars is determined by each individual ACO, providing financial incentives to primary care 
clinicians based on achievement of specific quality measures is a common approach.   Data 
regarding the impact of quality incentives are inconsistent though the size of the incentive is 
a likely predictor of impact.310   The impact of removing incentives has only been reported in 
one study from Kaiser Permanente in the United States.311   When incentives were 
introduced for cervical cancer screening in 1999 and 2000, screening rates increased slightly 
from 77.4% to 78.0%. They then fell back to 74.3% between 2001 and 2005 when incentives 
were removed, to increase again in 2006-2007 when incentives were reintroduced. 
In the United States, incentives linked to the quality of treatment for patients diagnosed 
with cancer are uncommon. Where incentives are used, they are directed to members of the 
treatment team and usually exclude primary care.  
 
The UK primary care pay for performance scheme312 contains two incentivised indicators of 
the quality of cancer care, namely that “practices should have a register of patients with 
cancer” and “the percentage of patients with cancer, diagnosed within the preceding 15 
months, who have a patient review recorded as occurring within 6 months of the date of 
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diagnosis”. The effectiveness of these measures – designed to strengthen the coordinating 
role of the primary care physician – is not known. 
 
An alternative approach to incentivisation is to provide patients with financial incentives, 
mainly to attend screening programmes. A systematic review has suggested that for 
mammography, cervical cytology and faecal occult blood screening, financial incentives to 
patients could increase uptake rates.313 
 
Conclusion 
While improvements in outcomes for and care of cancer patients have occurred there is 
more to be done building on past successes.  Variations in outcomes and access to services 
persist and these are generally poorer for older patients and those from deprived socio-
economic groups. Therefore countries with growing health inequalities and lacking universal 
health coverage are more likely to experience worse outcomes and poorer access to 
services. However, countries like the UK with universal health coverage has some of the 
highest health inequalities anywhere in the world with survival rates in England 10% lower 
than the European average with outcomes especially poor for older patients.  
 
The causes of these deficiencies, as in other healthcare systems, seem to be due to a 
complex mix of factors, including patient attitudes and behaviours and poorer access to, and 
possibly quality of, diagnosis and treatment services,.  The evidence concerning the 
importance of incentives is either mixed or lacking and they may be of limited utility in 
tackling the factors noted above.  Introducing and sustaining improvements to primary 
care’s gatekeeping role and attending to other aspects of the cancer care pathway may 
achieve greater gains and may be a better investment of resources. Finally, there is a need 
for further research to address important gaps in the international evidence base especially 
in regard to community and primary care policy initiatives and their impact.       
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Action points 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Health care systems must develop strategies that support primary 
care as the cornerstone in prevention, early detection, 
survivorship and palliative care   
 A focus on integrating primary and secondary cancer care is an 
important priority for health policy  
 Gatekeeper systems have an important impact on the role of 
primary care in many aspects of cancer control.  More research is 
needed on their impact on the quality of care   
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Part 9: Equipping primary care for its growing role in cancer care and control 
 
In a 2006 Lancet Oncology editorial, Barton et al discuss cancer as a growing public health 
problem and emphasize the critical role of PCPs in providing patient-centred care for people 
affected by cancer.314   PCPs are involved across the cancer care continuum from screening 
to end of life.   A 2009 survey of PCPs in the USA showed that over 90% provided general 
medical care for people with cancer, over 50% assisted patients with decisions about 
treatment options and use of surgery, and 19% reported heavy involvement in cancer 
treatment.315  
 
While the historic engagement of PCPs in cancer care provides some insights, it is insufficient 
to guide the future. Primary care will have to take a growing role in certain aspects of cancer 
care where previously it has been less involved, such as survivorship, palliation, and end of 
life care.  In the USA, a 40% growth in demand for cancer services is expected over the next 
20 years, with an increasing number of cancer survivors due to an aging population and 
improvements in cancer survival.316  However, PCPs will face challenges in assuming a wider 
responsibility for the care of patients in whom cancer is diagnosed or suspected.  None of 
these may be greater than the relative inattention to cancer education for generalist 
physicians, which begins in medical school, persists in specialty training, and continues in the 
domain of continuing professional development (CPD).  While the reasons for this 
inattention are undoubtedly complex, it is hard to ignore that cancer arguably has the most 
comprehensive, well resourced and self-sufficient system of patient care, research, and 
training of all the common diseases.  The very strength of this system and its willingness to 
stand somewhat apart may have had the inadvertent effect of weakening the ability and 
confidence of other parts of the system, including primary care, to care for cancer patients.   
Earlier in this Commission, we have detailed the evidence for the quality of cancer care and 
patient experience that could be delivered in primary care settings and the cancer care 
system is turning increasingly to primary care to play a larger role.   The challenge becomes 
one of equipping primary care for this work, and identifying the evidence-based educational 
strategies that will enable PCPs at all points in their training and practice to assume this 
responsibility.   
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Part 9 Panel 
 Cancer receives limited attention in undergraduate and registrar training and is seen 
as poorly taught. 
 Competencies need to be defined and taught at all stages of training and practice to 
equip PCPs for an extended role in cancer control. 
 Team-based approaches to training align well to the multi-professional makeup of 
primary care services. 
 Continuous quality improvement methods, such as audit and significant event 
analysis, can be integrated into the ‘work’ of primary care and are associated with 
optimal learning. 
 Educational interventions for PCPs should be embedded into new models of shared 
care. 
 Primary care itself – university departments, professional associations, vocational 
training systems – should take the responsibility for defining the cancer education 
needed for primary care trainees and practitioners 
 
 
Cancer in undergraduate education     
 Cancer education for PCPs begins formally in medical school.  Surveys in several countries 
regarding curricula demonstrate problems in undergraduate oncology teaching.317  In a 
recent Canadian survey, undergraduate oncology education was thought to be inadequate 
by 58% of curriculum leaders and 67% of medical students, and both agreed that oncology is 
the worst-taught of the medical subspecialties.318  Recommended oncology curricula for 
medical students have been developed and promoted within the USA, Australia and the UK.   
Innovative programs such as oncology summer schools,319 compulsory cancer medicine 
rotations,320 and pairing of students with tutors in multidisciplinary team cancer 
conferences321 have been developed both within and outside these curricula to address 
perceived deficiencies.  A stronger base of cancer education in undergraduate years will be 
necessary to support the role of all physicians, especially generalist physicians, in cancer 
care.  Our focus here, however, will be on the status of cancer-related education in 
registrar/residency training programs and in the realm of CPD for PCPs in practice.  It is 
instructive to review briefly the status of such education in key national jurisdictions.  
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Cancer in registrar training and CPD    
 In the UK, the postgraduate GP curriculum is overseen by the Royal College of General 
Practitioners (RCGP).  General practitioners (PCPs) in training need to provide evidence of 
learning against a series of "curriculum statements", summaries of what the RCGP considers 
is required to practise as an independent practitioner.  Cancer is no longer presented as a 
curriculum statement, as the curriculum addresses the principles of the discipline without 
covering all possible contexts.  Oncology is rarely included in GP trainee rotations, but all 
trainees will have gained exposure to the care of cancer patients during their GP 
placements.  The RCGP has however identified cancer as an ‘enduring priority’ and is 
developing educational resources for trainees and practitioners, such as the Cancer 
Education Hub.322  Other organizations, including the cancer charities, have also focused on 
primary care cancer education to support the CPD which is required by British PCPs as part 
of their revalidation.   This CPD is provided in a variety of formats: lectures, seminars, e-
learning and written material.  Although revalidation is mandatory, there is no requirement 
for cancer topics to be included in the practitioner’s portfolio.  A recent review of 
educational interventions for PCPs around early cancer diagnosis reported several types of 
educational interventions: didactic education, educational outreach, audit and feedback, 
interactive education, reminder systems and local opinion leaders.323 The review found 
limited evidence for long-term effectiveness of any of these interventions.   
 
In Canada, a 2014 survey of family medicine (FM) residents and residency program directors 
demonstrated that, of ten medical subspecialty areas, both groups rated oncology as the 
poorest taught in their specialty training and as the area in which residents were the least 
adequately prepared for their role in patient care.324  No Canadian FM training programs had 
a mandatory oncology rotation or recommended text or reference resource, and only two 
had a set of oncology objectives for their learners.   Nationally, the College of Family 
Physicians of Canada (CFPC) has enunciated 99 priority topics that serve as examination 
objectives for FM residents.  Cancer is one of these areas, with seven "key features" 
identified..  Where CPD is concerned, several provincial cancer agencies have developed 
primary care education and liaison programs325 These programs offer cancer education 
programs aimed at practitioners, with one publishing a comprehensive FP learning needs 
assessment.326   Nationally, the CFPC has formed a Cancer Care Program Committee which 
sponsors cancer-related CPD sessions at its national meeting. 
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The Royal Australian College of General Practitioners (RACGP) has recognized the 
importance of oncology in its Curriculum for Australian General Practice. It details training 
outcomes in oncology across a PCP’s professional life from medical student, prevocational 
doctor, vocational registrar to independent practitioner. The curriculum includes the 
continuum of cancer care in general practice as one of its 34 chapters. Vocational training 
for PCPs in Australia is run by local training providers (such as the Victorian Melbourne 
Alliance) who determine its detailed content, with national oversight by Australian General 
Practice Training and the Remote Vocational Training Scheme. Thus, although oncology is an 
examinable subject in the RACGP Fellowship examination, there will be significant variation 
across training providers in terms of time spent addressing learning in oncology.  From the 
perspective of CPD, some State-based Cancer Councils deliver PCP education programs 
which are mainly seminar-based.  Other more innovative programs have been introduced.  
In Western Australia, brief oncology placements for PCPs have been established focused on 
learning about common side-effects of chemotherapy and their management. To better 
meet the needs of rural PCPs, Cancer Australia, a federal cancer agency, has developed an 
online ‘Education Program in Cancer Care’.327 
 
In summary, several jurisdictions have formalized oncology-related learning outcomes for 
registrar training.  These necessarily must compete for attention with many other priorities 
in crowded general practice training programs, and in some jurisdictions are seen as being 
more poorly taught than other topic areas.  Cancer authorities and charities are often the 
taking the lead in offering cancer-related CPD to primary care. Given this present reality, it is 
pertinent to ask two fundamental questions.  First, what are the present trends and best 
practices in both registrar training and in CPD that will need to be capitalized on to equip 
primary care to play a larger role in cancer care?  Second, who should take the lead in 
ensuring that this education happens?   
 
Trends in medical education    
Competency-based education is marked by an emphasis on the demonstration of outcome 
abilities and is organized around competencies derived from an analysis of societal and 
patient needs.  It de-emphasizes time-based training and promises greater accountability, 
flexibility, and learner centredness.328  While the main focus of this approach has been on 
postgraduate training,329 these training periods are short, and advanced competencies need 
to be defined by and for physicians in practice to provide guidance for CPD.330  Examples of 
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emerging competencies for practising PCPs include areas outlined earlier in this Commission: 
the  application of tools such as QCancer and RATs to perform risk assessments of possible 
cancer symptoms, incorporation of genetic risk assessment tools into practice, screening for 
distress and psychosocial difficulty in cancer patients, and surveillance and management of 
both long term and delayed, "late effects" of cancer treatment.  These advanced 
competencies for practitioners should build on those described for undergraduate and 
postgraduate learning, in the manner of the RACGP Curriculum described earlier.  They need 
to reflect broadly defined physician roles such as those enunciated in the Canadian 
CanMEDS Competency Framework,331 particularly the 'communicator' and 'collaborator' 
roles that are central to cancer care.   
 
Trends in practice organization and education 
Team-based approaches to health care are driven by the intuitive conclusion that clinical 
practice is too complicated to be managed by any single practitioner.  Cancer care is one of 
the better examples of an area that requires both technical expertise and multifaceted 
knowledge of an individual and their family. Teams that can divide functions and expertise 
but serve a common locus for care for the patient are therefore a solution that may better 
address the needs of patients and practitioners themselves. The key however is creating a 
team that shares a common goal and manages the interdependent tasks of caring for a 
single individual over time.  Such tasks could include the management of cancer 
rehabilitation, co-morbid conditions, alleviation of symptoms, and the anticipation of end of 
life care.   As interest and promotion of team based care has grown, there has also been a 
corresponding emergence of team-based education, or "team training."  In the USA, 
TeamStepps was created by the Agency for Healthcare Research and Quality to promote 
increased safety in medical practice.332 This workplace-based program encourages teams to 
assess themselves and their environment, and provides education regarding the skills 
fundamental to successful teamwork.  These include situational awareness, closed loop 
communication, mutual support, and team structure.  A large body of literature 
demonstrates the success of such training in achieving improved skills and reduced errors in 
a variety of settings.333-335  The application of team-based education for the care of cancer 
patients in primary care is a promising approach that builds on the increasingly 
interprofessional makeup of primary care services in many countries.  
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Practice audits and performance feedback in primary care  
 The movement towards quality improvement in the UK has a particular concern with 
enhancing patient safety, and includes a number of continuous improvement techniques 
which have been adapted for issues in cancer care.  These methods include clinical audit and 
significant event analysis, both of which are required to be undertaken by PCPs as part of 
the revalidation process.  The RCGP has been instrumental in leading a national cancer 
audit336 and developing "significant event audits" for general practice triggered by new 
diagnoses of cancer in the practice (Box 9.1).138  These tools ask PCPs to review their own 
practice of cancer diagnosis, to reflect on it and to  identify opportunities for 
improvement.  Other types of feedback systems utilize data about practice that is derived 
from electronic health records or patient surveys.  This allows a physician to compare their 
practice with that of peers and/or to an outside standard.  A strength of these feedback 
systems is their reliance on frequent, personalized feedback, that in adult education terms is 
associated with optimal learning.  In many jurisdictions, these kinds of CPD activities also 
garner a higher level of CPD credit than traditional group learning activities.   These feedback 
and audit techniques form part of a larger movement towards "practice-based CME" which 
features learning at the point of care, woven into the rhythms of the workplace rather than 
in a distant lecture theatre.   This broader category also includes clinical decision support 
systems, which have been shown to have a powerful effect on physician performance and 
are discussed in more detail in the section on Early Diagnosis. 
   
 
 
 
 
 
 
 
 
 
Box 9.1 Significant event analysis 
 
 
 
 Significant Event Analysis for cancer 
  
 This team-based quality improvement technique asks the following questions: 
 What happened and why?  
 How could things have been different  
 What can we learn from what happened?  
 What needs to change?  
 What was the impact on those involved (patient, carer, family, GP, practice)?  
SEA team discussions are an opportunity for the primary care team to: 
 - discuss each stage of the diagnosis in detail  
 - identify any learning needs  
 - identify actions to be taken and changes to be made and agree how these will be 
progressed.  
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Education embedded in new models of shared care 
New models of shared care among primary care and oncology are being developed to meet 
the growing demand for cancer services and the relative shortfall in oncologists.337   Such 
models involve renewed attention to information transfer that can also function as high 
quality continuing education for PCPs.  Reminder systems provide patient-specific 
communication from an expert source to an individual physician or a team at the point and 
time of care, and provide a recommendation regarding the need for a specific test, exam, or 
procedure.   The provision of tailored chemotherapy information to PCPs after the initial 
oncology consultation has been shown in a randomized trial to improve the confidence of 
PCPs in managing adverse effects and their satisfaction with shared care, although improved 
knowledge was not demonstrated.265  Similarly, a 2009 survey in the USA demonstrated that 
PCPs who always or almost always receive a "survivorship care plan" from the oncology 
team reported greater confidence in patient management and care co-ordination across a 
range of responsibilities.338  As new shared care models develop at different points in the 
cancer care continuum, opportunities should be taken to develop patient-specific 
educational interventions for PCPs that can be certified as CPD activities and that function in 
primary care electronic health records. 
 
Taking the lead in cancer education for primary care 
Primary care trainees and practitioners must be equipped to play a growing role in cancer 
care and control, and developments in the practice and educational environments should be 
harnessed to support this goal.  But who should take the lead in providing the kind of cancer 
education for primary care trainees and physicians that has been described?  In many 
jurisdictions, the impetus for this work has come from cancer charities and authorities, with 
the energetic support of PCPs invited into their work.  With the large number of competing 
health priorities that individual PCPs and their associations need to respond to on a weekly 
basis, it is not surprising that the push to address this educational gap has come from the 
cancer system.  The danger, though, is that this focus can be viewed as special pleading by 
an interest group, and not the authentic voice and concern of primary care itself.  Cancer has 
become the leading public health challenge in developed countries.  In Canada, for example, 
cancer is the leading cause of death and also the leading cause of premature death, with the 
greatest burden of disease and years of life lost of any illness.339  This enormous challenge 
requires primary care itself to take the lead, in our university departments of general 
practice/family medicine, our professional associations, and in our vocational training 
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systems.   The example of the Royal College of General Practitioners in the UK is exemplary, 
which has benefited from a social consensus on the importance of improving cancer 
outcomes and from the influence and energy of key academic PCPs on making cancer care 
an organizational priority.  Rather than sitting back, primary care needs to take the lead in 
equipping itself both in its registrar training and CPD programs for its central role in 
improving cancer outcomes and the quality of cancer care.  
 
Action points 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Undergraduate and training curricula need to be reviewed to 
ensure that they adequately prepare PCPs for their future role 
in cancer control 
 Audit and performance feedback should become a core 
function of primary care teams froviding cancer care 
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Part 10: Conclusions and recommendations 
Primary care is continuous, co-ordinated and comprehensive care for individuals and families, 
from  the first contact for health care through to the end of life. It is an integral part of the care 
of all disease, to a greater or lesser extent and at different stages of the illness. Crucially, the 
PCP is the key interface between the patient and specialist care, facilitating timely and 
appropriate access and sometimes protecting that patient from unnecessary or inappropriate 
interventions. At the same time, the PCP is the one healthcare professional whose role is to 
provide whole-person, rather than disease-centred care, and to place his contribution to the 
care of a person’s cancer in the context of their  other physical, emotional and social needs.   
The highly technical interventions that surround diagnosis and treatment of cancer have long 
been the focus of innovation in care. But patients also want care that is co-ordinated, with a 
clear and seamless journey between care settings.340 They want care that is close to home 
where possible, and is accessible when they need it, whatever the stage of their cancer 
journey.  They want continuity of care, in the informational and organisational as well as the 
relational senses of the term.341 
 
This Commission has identified aspects of care at all stages of the cancer pathway where there 
is good evidence for the positive benefits of input from primary care.  The possibilities and 
benefits are potentially wide-ranging (Table 1). There is evidence in the United States that long 
term cancer survivors who see both oncologists and primary care providers are more likely to 
get the full array of care they need: prevention, care of comorbid conditions, appropriate 
surveillance for treatment effects and recurrence.342 This fact alone should motivate models of 
shared care, but the demand for oncologic care is also anticipated to grow by 40% in the next 
20 years while the population of oncologists will only grow by 25%.316, 337 It is too simplistic to 
assume that substitution is the solution, when demand for primary health care is also rising, 
but the models of shared care described, for follow up, survivorship, and end of life care in 
particular, offer better ways of meeting this need.  
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Challenges Possible solutions from primary care 
Rising incidence of cancer and 
considerable increase in the number of 
patients surviving cancer 
Integrated care, particularly for follow-up, 
underpinned by guidelines for best practice 
Primary prevention offers considerable 
potential for reducing incidence but is not 
well implemented 
Effective models developed for 
incorporating primary prevention into 
routine practice 
Patient –related delays are an important 
component of overall time to diagnosis 
Access to primary care configured to 
minimise barriers to consultation 
Variations and inequalities in uptake of 
cancer screening 
Wider sharing and implementation of best 
practice, especially in the contribution of 
the PCP to promoting population-based 
screening programmes 
Symptoms that could be cancer are 
common in primary care, but cancer is rare 
Those symptoms with a low PPV for cancer 
present a particular challenge 
Development and systematic application of 
electronic clinical decision support to select 
patients for urgent assessment, together 
with tools to overcome cognitive error. 
A range of models for access to diagnostics 
is developed to accommodate differing 
levels of risk. 
Follow-up care requires expertise in cancer 
but also in its wider physical and 
psychological sequelae 
Integrated models of follow up care with 
embedded CPD for PCP.  
PCPs work in wider networks or 
federations to enable sharing of expertise 
People will continue to die as a result of 
cancer, and wish to die in comfort and at 
home 
Integrated working with palliative care, 
underpinned by CPD and the breaking 
down of logistical barriers in primary care 
Table 10.1 Cancer care challenges and possible primary care solutions  
 
Indeed, the dominant theme of this review is of integration of care. Such models have existed 
in mental health for a generation.343 They are widely applied in chronic disease management in 
Europe, but they have not been implemented in cancer. In part 7 we describe in detail the 
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principles of integrated care, how it can be implemented and why it is vital if quality of care 
and outcomes for cancer are to improve.  
 
Fundamental to sharing care is addressing transitions in care.  These transitions occur when 
information and responsibility needs to be transferred between groups or settings; when a 
cancer screening abnormality is found on mammography, when someone is discharged from 
the hospital, when a symptom we see in primary care needs to be evaluated in oncology.337, 
344  Such transitions occur across the cancer continuum and they are recognized as a source 
of failures in care by any clinician in practice.249 Despite their widespread recognition, there 
is little evidence regarding how to measure them or their effects. For example, failures in 
follow-up to abnormal screening tests for breast, colon, and cervical cancer are widespread 
in the US.345  We need metrics of failures at critical transitions in cancer care to help us 
address the challenges they represent.  
 
One of the key roles for the PCP is in the initial assessment of the patient who might have 
cancer. Around 90% of patients present first with symptoms in primary care. The likelihood 
of cancer, even with so-called ‘alarm’ symptoms is small in adults and smaller still in 
children, teenagers and young adults. In parts 3 and 4 we identified the approaches being 
taken to support clinicians in achieving earlier and more accurate diagnosis. There has been 
much innovation but there remains more to be done, particularly for those cancers with a 
weak symptom signature, where a step change in diagnostic technology may offer the 
greatest prospect of significant improvement. At present the development of increasingly 
sophisticated clinical decision support tools, together with referral pathways that offer 
flexibility in the options for assessment, offer the best prospects of quality improvement. For 
some cancers, however, new diagnostic biomarkers or screening modalities are awaited. 
 
Two last considerations are key if care integration for cancer is to become a reality. Firstly, 
health policy needs to actively involve community-based provision of services, and ensure 
that high quality primary care is available, affordable, trusted and valued by the public. The 
means by which this is achieved include ensuring good access to primary care, the 
organisation of gatekeeping systems so to enable rather than restrict access to secondary 
care, and different approaches to incentivisation. Secondly, the curriculum relevant to 
cancer care within undergraduate, post-graduate and CPD programmes is variable in its 
depth and breadth. A more consistent approach between countries could contribute to 
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reducing inequalities in outcomes. . In some countries the performance of PCPs is called into 
question over the roles they currently play, especially in cancer diagnosis, and forms the 
basis of objections to a more extended role. The evidence now largely refutes this, while the 
sub-optimal performance of a small minority is a feature of all medical specialties and no 
grounds for limiting the scope of their practice.  Performance review through clinical audit 
and feedback are well accepted tools for quality improvement in primary care but have been 
little used in the field of cancer care.  
 
Much remains to be better understood. We need evidence for the clinical and cost-
effectiveness of risk thresholds of urgent investigation, and for the effectiveness of risk 
assessment tools in supporting that selection process. Specifically, we need to understand 
the means by which the research to date can be translated into standard practice and its 
clinical and cost-effectiveness in pragmatic settings.  Initiatives to support multi-disciplinary 
research capacity will be essential to delivering that research. In Australia, for example, the 
Primary Care Collaborative Cancer Clinical Trials Group (PC4, http://www.pc4tg.com.au/) 
supports research capacity building and the development of trials of interventions across the 
cancer continuum in primary care.  
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